On this page
Quick Reference
Overview and Recommendations
Background
- •Recognize rabies as a fatal caused by the rabies virus (RABV) and other lyssaviruses, which are bullet-shaped, single-stranded RNA viruses that are exquisitely neurotropic.
- •Identify the primary global reservoir as the domestic dog, responsible for 99% of human deaths, while recognizing that in the Americas, bats are the most frequent source of human infection.
- •Understand the unique pathophysiology involving retrograde axonal transport, where the virus travels from the site of inoculation to the spinal cord and brain at a rate of approximately 12–100 mm per day.
- •Differentiate between the two clinical phenotypes: the encephalitic (furious) form, characterized by agitation and hydrophobia (80% of cases), and the paralytic (dumb) form, characterized by ascending weakness (20% of cases).
- •Note the highly variable incubation period, which typically lasts 20 to 90 days but can range from less than one week to over one year depending on the viral load and the proximity of the bite to the central nervous system.
- •Acknowledge the "Zero by 30" global initiative, which aims to eliminate dog-mediated human rabies deaths by 2030 through mass dog vaccination and improved access to human biologics.
Evaluation
- •Suspect rabies in any patient presenting with acute, progressive neurological symptoms, especially if they have a history of animal contact or have recently traveled to an endemic region.
- •Ask specifically about the "bite history," including minor scratches or licks on broken skin, and note that patients may not recall an exposure, particularly with bats, which have small teeth that leave minimal marks.
- •Look for the pathognomonic early sign of localized paresthesia, pain, or intense pruritus at the site of the original (and often healed) exposure, which occurs in about 50% of patients.
- •Perform a "water test" to provoke hydrophobia: offer the patient a glass of water and observe for violent, involuntary spasms of the diaphragm and pharyngeal muscles triggered by the attempt to drink.
- •Assess for aerophobia by fanning a draft of air across the patient's face, which may trigger similar spasmodic gasping or psychomotor agitation.
- •Evaluate for autonomic instability, including "autonomic storms" characterized by hypersalivation (foaming at the mouth), profuse sweating, and fluctuating blood pressure or heart rate.
- •Distinguish paralytic rabies from by noting the presence of fever, early bladder dysfunction, and the relentless progression to coma in rabies, whereas GBS often lacks these features.
- •Order antemortem diagnostic testing including RT-PCR of saliva (collect three samples 3–6 hours apart) and a full-thickness nuchal skin biopsy (3–5 mm) from the posterior hairline to detect viral antigen in cutaneous nerves.
- •Obtain serum and cerebrospinal fluid (CSF) for rabies virus neutralizing antibodies (RVNA); the presence of antibodies in the CSF is highly specific for rabies encephalitis in both vaccinated and unvaccinated individuals.
- •Utilize Magnetic Resonance Imaging (MRI) to rule out other causes of encephalitis; while often normal early on, rabies may eventually show T2-hyperintensities in the brainstem, hippocampus, and gray matter.
- •Rule out other differential diagnoses such as Japanese encephalitis, , cerebral malaria, and acute drug toxicity (e.g., poisoning).
Management
- •Categorize the exposure immediately: Category I (touching/licking intact skin) requires no treatment; Category II (minor scratches without bleeding) requires immediate vaccination; Category III (transdermal bites/scratches or bat contact) requires vaccination plus immunoglobulin.
- •Wash all wounds immediately and thoroughly with soap and water or povidone-iodine for at least 15 minutes; this mechanical action is the most critical step in reducing viral load.
- •Administer Human Rabies Immunoglobulin (HRIG) at a dose of 20 IU/kg (or Rabies Monoclonal Antibodies at 0.3 mg/kg) for all Category III exposures in previously unvaccinated individuals.
- •Infiltrate the entire dose of HRIG into and around the wound site; if the volume is insufficient for multiple wounds, dilute it in sterile saline to ensure adequate coverage of all injury sites.
- •Initiate the rabies vaccine series (Essen regimen) with intramuscular injections (0.5 or 1.0 mL depending on product) on days 0, 3, 7, and 14 for immunocompetent patients.
- •Add a fifth vaccine dose on day 28 for immunocompromised patients and monitor serology to ensure the RVNA titer reaches the protective threshold of ≥ 0.5 IU/mL.
- •Provide a 2-dose booster series (days 0 and 3) for previously vaccinated individuals who experience a new exposure; these patients do NOT require rabies immunoglobulin.
- •Administer antibiotic prophylaxis (e.g., Amoxicillin-clavulanate 875/125 mg twice daily for 3–5 days) for high-risk animal bites to prevent secondary bacterial infection from oral flora like Pasteurella.
- •Admit symptomatic patients to a quiet, low-stimulus isolation room to prevent triggering painful spasms and to protect healthcare workers from contact with infectious saliva.
- •Manage agitation and spasms with heavy sedation using benzodiazepines (e.g., Diazepam 5–10 mg IV every 4–6 hours) or antipsychotics (e.g., Haloperidol).
- •Avoid the "Milwaukee Protocol" (therapeutic coma), as multiple clinical trials have shown it is ineffective and does not improve survival.
- •Provide aggressive palliative care, including IV fluids for hydration and opioids for pain, ensuring a dignified end-of-life process for the patient and support for the family.
- •Notify public health authorities immediately of any suspected human or animal rabies case to facilitate contact tracing and environmental control measures.
- •Refer all symptomatic cases to a tertiary care center with intensive care capabilities, though the prognosis remains near-universally fatal regardless of the level of care.
Board Review — High Yield
- •Negri bodies — Eosinophilic cytoplasmic inclusions in neurons (hippocampus/cerebellum) pathognomonic for rabies.
- •Retrograde axonal transport — The mechanism by which the virus travels from the periphery to the CNS via dynein motors.
- •Nicotinic acetylcholine receptor — The primary receptor at the neuromuscular junction used by the rabies virus for entry.
- •Hydrophobia — Involuntary pharyngeal spasms triggered by the sight or sound of water; classic sign of encephalitic rabies.
- •Bat exposure — PEP is indicated even if a bite is not felt if a person was in a room with a bat and cannot rule out contact (e.g., sleeping, intoxicated).
- •Category III Exposure — Requires both vaccine and RIG; RIG must be infiltrated into the wound.
- •Incubation period — Highly variable (days to years), but typically 1–3 months.
- •Vaccine type — Modern rabies vaccines are inactivated (killed) virus grown in cell cultures (e.g., Vero cells).
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸Rabies is a zoonotic encephalitis with the highest case fatality rate of any infectious disease, approaching 100% once symptoms appear.
- ▸The disease is caused by neurotropic RNA viruses in the genus Lyssavirus, family Rhabdoviridae.
- ▸Clinical presentation is broadly categorized into 'Furious' (agitated) and 'Paralytic' (dumb) forms.
Rabies is an acute, progressive, and invariably fatal zoonotic viral encephalitis caused by neurotropic RNA viruses of the genus Lyssavirus [4]C[6]D[16]D. The disease is characterized by its quintessential neurotropism, where the virus establishes an incurable infection of the central nervous system (CNS) following exposure through the bite or scratch of an infected animal [6]D[23]D. With a history dating back 4,000 years, rabies remains one of the most significant pathogens in public health, agriculture, and conservation biology due to its 100% case fatality rate once clinical symptoms manifest [6]D[12]D[26]D.
Synonyms and Alternate Names
Historically and clinically, rabies is known by several names that reflect its characteristic symptoms or taxonomic origin:
- Hydrophobia: Derived from the Greek for "fear of water," referring to the intense, painful spasms of the throat (dysphagia) triggered by attempts to drink [30]D.
- Lyssa: From the Greek lyssa (frenzy or madness), which serves as the namesake for the genus Lyssavirus [6]D[25]D.
- Rage: The French term for the disease, commonly used in historical medical literature [6]D.
Clinical Phases and Progression
The progression of rabies follows a predictable sequence of stages, though the duration of each can vary significantly depending on the viral load and the distance of the inoculation site from the CNS [6]D.
- Incubation Period: The asymptomatic phase between initial exposure and the onset of clinical signs. During this time, the virus may replicate locally before undergoing retrograde axonal transport to the spinal cord and brain [6]D.
- Prodromal Phase: The first clinical stage, lasting 2 to 10 days. Symptoms are non-specific and include fever, malaise, headache, and distress. A key diagnostic indicator is paresthesia, pruritus, or pain at the site of the original exposure [4]C[5]C.
- Acute Neurological Phase: This phase is divided into two primary clinical forms: Furious (Encephalitic) and Paralytic (Dumb) rabies. Furious rabies is characterized by psychomotor agitation, hydrophobia, aerophobia, and fluctuating consciousness [2]C[4]C. Paralytic rabies, seen in approximately 20% of cases, presents with ascending muscle weakness and paralysis, often mimicking [3]C.
- Coma and Death: The terminal stage where progressive encephalitis leads to multi-organ failure, respiratory arrest, and death, typically within 7 to 14 days of symptom onset [2]C[6]D.
Classification of Lyssaviruses
Rabies is caused by viruses in the family Rhabdoviridae, genus Lyssavirus [6]D[14]D. While the classic rabies virus (RABV) is the most common cause of human infection, several other lyssaviruses cause an identical clinical syndrome [6]D. These are often categorized by their epidemiological cycles: the terrestrial cycle (maintained by carnivores like dogs, foxes, and jackals) and the aerial cycle (maintained by bats) [13]D[16]D.
Variants and Antigenic Profiles
In the Americas, rabies is exclusively maintained by bats and terrestrial wildlife, as dog-mediated rabies has been largely eliminated in many regions [18]D[26]D. Variants are often identified by their antigenic profiles using monoclonal antibodies or genetic sequencing of the nucleoprotein (N) gene [12]D[24]D.
| Virus/Variant Name | Primary Reservoir | Key Distinguishing Feature | Associated Antigenic Profile |
|---|---|---|---|
| Rabies virus (RABV) | Dogs, Bats (Americas), Carnivores | Global distribution; most common cause of human rabies [4]C[16]D | Multiple (e.g., V3, V4, V6) |
| Irkut virus (IRKV) | Bats (Russia/East Asia) | Causes fatal encephalitis with psychomotor agitation and aphasia [2]C | IRKV-specific |
| Divača bat lyssavirus | Long-fingered bat (Myotis capaccinii) | Recently discovered in Slovenia; 11,871 nucleotide genome [25]D | DBLV-specific |
| Variant 3 (V3) | Vampire bat (Desmodus rotundus) | Associated with paralytic rabies in livestock and wildlife [3]C | Variant 3 |
| Variant 4 (V4) | Brazilian free-tailed bat (T. brasiliensis) | Common insectivorous bat variant in the Americas [13]D | Variant 4 |
| Variant 6 (V6) | Red bat (Lasiurus varius) | Circulates in insectivorous bats in Patagonia and South America [13]D | Variant 6 |
| Stage | Duration | Key Features | Reasoning/Mechanism |
|---|---|---|---|
| Incubation | Weeks to Months | Asymptomatic | Retrograde axonal transport to the CNS [6]D |
| Prodromal | 2–10 Days | Fever, pruritus at bite site | Viral entry into the CNS and early replication [4]C[5]C |
| Progressive | 2–7 Days | Agitation or ascending paralysis | Acute encephalitis and neuronal dysfunction [2]C[6]D |
| Terminal | 1–2 Days | Coma, respiratory failure | Brainstem involvement and autonomic collapse [2]C[4]C |
Epidemiology and Risk Factors
- ▸Rabies causes approximately 60,000 deaths annually, with 95% of cases occurring in Asia and Africa.
- ▸Dogs are the primary vector, responsible for 94-99% of human cases, though wildlife reservoirs like foxes and bats maintain environmental circulation.
- ▸Socioeconomic disadvantage and rural residence are the strongest predictors of rabies mortality and PEP non-adherence.
Rabies is a nearly 100% fatal, vaccine-preventable disease that remains a critical global public health challenge, particularly in low- and middle-income countries [43]D[51]D. While the disease is theoretically eliminable through mass dog vaccination and timely (PEP), it continues to cause approximately 59,000 to 60,000 human deaths annually [33][38]D[51]D. The vast majority of these cases—roughly 95%—occur in developing regions of Asia and Africa [33][51]D.
Global Incidence and Temporal Trends
Global rabies incidence and age-standardized incidence rates (ASIR) have shown a significant decline over the last three decades, decreasing by 53.8% and 69.4% respectively between 1990 and 2021 [44]D. Despite this overall progress, the burden remains highly unequal. In China, for example, a steady decline in human cases was observed from 2008 through 2023 following comprehensive control measures; however, 2024 witnessed a 36.9% increase in cases compared to 2023, suggesting potential shifts in transmission dynamics or a lapse in control effectiveness [49]D. In Ethiopia, the disease remains highly endemic, though pooled incidence rates vary significantly by region [31]. Conversely, some nations have successfully eliminated rabies as a public health problem, contributing to the 50 countries that have eliminated at least one neglected tropical disease (NTD) by 2024 [52]D.
Demographic Distribution
Rabies disproportionately affects vulnerable populations, with age, socioeconomic status, and geography serving as primary determinants of risk.
- Age: Children are at the highest risk of exposure and death, often due to closer interactions with dogs and a lack of awareness regarding the need to report bites [38]D[51]D. However, specific risks for PEP delay have been noted in adults; for instance, individuals aged 35–60 years have an adjusted odds ratio (AOR) of 3.08 for delayed PEP initiation [34].
- Socioeconomic Status (SES): There is a direct correlation between poverty and rabies risk. High-spatial-resolution data indicates that rabies cases are concentrated in socioeconomically disadvantaged neighborhoods [41]D. Marginalized communities, such as those in tea estates in India or refugee settlements like Cox’s Bazar, face heightened risk due to unmanaged dog populations and limited healthcare access [38]D[46]D.
- Geography: Rural areas bear the brunt of the disease. In Tunisia, 77% of confirmed human cases between 2000 and 2022 occurred in rural settings [53]D. This is often due to the proximity of domestic animals to wildlife reservoirs and the distance from medical centers providing PEP [53]D[55]D.
Animal Reservoirs and Transmission Dynamics
While all warm-blooded animals are susceptible, the primary reservoirs vary by geography. Dogs remain the most significant vector for human infection, responsible for nearly 99% of all human rabies deaths globally [38]D. In a study of Chinese human rabies cases, 94.0% of incidents involved dog wounds, and 48.5% of those animals were domestic pets from the victim's own residence [60]D.
Wildlife reservoirs play a critical role in maintaining the virus in the environment. In Asia, the test prevalence of rabies in tested animals is approximately 23%, with foxes showing the highest prevalence at 45% [33]. In the United States (specifically Georgia), wildlife species account for the majority of positive cases, including raccoons, skunks, and bats, while domestic animals account for only 17% of laboratory-confirmed cases [57]D.
Risk Factors for Exposure and PEP Failure
The transition from exposure to clinical rabies is influenced by the characteristics of the wound and the speed of the medical response. Factors that increase the likelihood of PEP failure or delay include the site of exposure ( and neck wounds have shorter incubation periods) and the severity of the wound [39]D.
| Risk Factor | Association | Evidence Level |
|---|---|---|
| Age 35–60 years | AOR 3.08 for delayed PEP | 2b [34] |
| Superficial Wounds | AOR 2.86 for delayed PEP | 2b [34] |
| Single Wound | AOR 1.88 for delayed PEP | 2b [34] |
| Low Socioeconomic Status | Increased case positivity | 5 [41]D |
| Rural Residence | 77% of cases in endemic regions | 5 [53]D |
| Category III Exposure | High risk of failure without RIG/mAbs | 1b [35] |
Seasonal and Environmental Variation
Rabies transmission often exhibits seasonal patterns, though these vary by climate and local animal behavior. In some regions, animal bite cases show a nearly two-fold increase during specific months, often correlating with animal breeding seasons or human agricultural activities [58]D. In the United States, wildlife rabies cases often peak in the spring and summer months [57]D. Furthermore, the pandemic significantly altered transmission patterns; nonpharmaceutical interventions (NPIs) like lockdowns temporarily reduced the incidence of many zoonotic diseases, but the subsequent lifting of these measures has seen a rebound in cases in some provinces [42]D[55]D.
| Factor | Statistical Measure | Clinical Outcome |
|---|---|---|
| Age (35–60 years) | AOR 3.08 | Delayed PEP initiation |
| Superficial Wounds | AOR 2.86 | Delayed PEP initiation |
| Single Wound | AOR 1.88 | Delayed PEP initiation |
| Rural Setting | 77% of cases | Increased exposure risk |
| Domestic Dogs | 94% of bites | Primary transmission source |
Etiology and Triggering Factors
- ▸Domestic dogs remain the primary etiological trigger for human rabies globally, accounting for nearly 99% of cases.
- ▸The Rabies virus (RABV) Phosphoprotein (P) is a key virulence factor that antagonizes the host's interferon response to facilitate CNS invasion.
- ▸Human-to-human transmission is rare but documented through solid organ transplantation from undiagnosed donors.
Rabies is an acute, progressive, and nearly universally fatal viral encephalitis caused by neurotropic viruses in the genus Lyssavirus, family Rhabdoviridae [6]D[66]C. The primary etiological agent is the Rabies virus (RABV), a single-stranded, negative-sense RNA virus characterized by a distinct bullet-shaped morphology [6]D[78]D. While RABV is the most common cause, other lyssaviruses, such as the Irkut virus (IRKV), can produce an identical clinical syndrome of fatal encephalitis following exposure to reservoir species like bats [2]C. The etiology of rabies is defined by the spillover of these viruses from animal reservoirs to humans, primarily through the inoculation of infected saliva into tissues [61]D[68]D.
Primary Viral Mechanisms
The pathogenicity of RABV is driven by its structural proteins and their interaction with the host central nervous system (CNS). The Glycoprotein (G) is the sole protein on the viral surface and is essential for receptor binding and entry into host cells [73]D. The Phosphoprotein (P) serves as a critical non-catalytic cofactor for the viral polymerase (L protein), facilitating genome replication and transcription while simultaneously acting as a potent antagonist of the host's interferon-mediated innate immune response [72]D. Recent proteomics have identified that RABV virions entrap specific host proteins, such as Neuromodulin, Chmp4b, and DnaJB6, which may facilitate immune evasion and viral pathogenicity [79]D. Furthermore, neurotropic viruses like RABV can modulate the (BBB) integrity, creating a permissive environment for viral spread and potentially altering the CNS microenvironment [63]D.
Transmission Dynamics and Portals of Entry
Transmission occurs when the virus, present in the saliva or tissues of an infected host, gains access to the recipient's nervous system. The following protocols outline the assessment of etiological triggers:
Protocol for Exposure Assessment:
- Step 1: Identify the Exposure Type — Determine if the contact involved a transdermal bite, scratch, or mucosal contact with saliva [66]C[67]C.
- Step 2: Characterize the Vector — Identify the animal species (e.g., dog, bat, cat) and its behavior (provoked vs. unprovoked) [62]D[64]C.
- Step 3: Evaluate Non-Bite Risks — Assess for rare routes such as organ transplantation, aerosol inhalation in high-density bat caves, or ingestion of raw animal products [65]C[66]C.
Reservoir Hosts and Epidemiological Cycles
Rabies is maintained in two distinct but overlapping epidemiological cycles: the terrestrial cycle and the aerial cycle [13]D[18]D.
Terrestrial Reservoirs
- Domestic Dogs: Responsible for approximately 99% of human rabies deaths globally, particularly in Asia and Africa [61]D[68]D. Dog-mediated rabies is the target of global elimination efforts by 2030 [61]D.
- Domestic Cats: Cats serve as incidental hosts and important vectors but are not considered primary viral reservoirs [62]D. They typically acquire the virus from local terrestrial or aerial reservoirs [62]D.
- Wildlife Carnivores: Species such as the black-backed jackal (Canis mesomelas), bat-eared fox (Otocyon megalotis), yellow mongoose (Cynictis penicillata), and skunks maintain specific viral lineages [16]D[65]C. In North America, the North Central Skunk variant is a recognized trigger for livestock clusters [69]D.
- Livestock: Cattle, equines, and even rare species like the lowland tapir (Tapirus terrestris) can be infected, often serving as dead-end hosts that pose a risk to agricultural workers [3]C[68]D[69]D.
Aerial Reservoirs (Bats)
Bats are the natural reservoirs for the aerial cycle and are the exclusive source of bat-associated RABV variants in the Americas [18]D.
- Vampire Bats (Desmodus rotundus): A major source of Antigenic Variant 3, which frequently spills over into livestock and humans in Latin America [3]C[71]D.
- Insectivorous Bats: Species such as Tadarida brasiliensis and Myotis species maintain diverse RABV variants [10]D[13]D[18]D. Migration patterns of these bats facilitate the wide geographic distribution of the virus [10]D.
Rare and Emerging Etiological Triggers
- Human-to-Human Transmission: While rare, rabies can be transmitted via solid organ transplantation (e.g., kidneys) from undiagnosed donors [65]C[66]C.
- Non-RABV Lyssaviruses: The Irkut virus (IRKV) has been documented to cause fatal human cases in the Russian Far East following bat bites, presenting with symptoms like psychomotor agitation and dysphagia [2]C.
- Unconventional Routes: Inhalation of aerosolized particles in laboratory settings or caves, and the ingestion of contaminated raw animal products, are documented but infrequent triggers [66]C.
| Cause | Category | Frequency | Associated Subtype/Variant | Key Reference |
|---|---|---|---|---|
| Rabies Virus (RABV) | Viral (Rhabdoviridae) | >99% of cases | Multiple (e.g., Africa-1a, Africa-1b) | [6]D[19]D[66]C |
| Domestic Dog Bite | Terrestrial Zoonosis | Most Common | Dog-mediated variants | [61]D[68]D |
| Bat Bite/Scratch | Aerial Zoonosis | Common (Americas) | Variant 3 (Vampire bat), V4, V6 | [3]C[13]D[18]D |
| Organ Transplant | Human-to-Human | Very Rare | Donor-acquired variant | [65]C[66]C |
| Irkut Virus (IRKV) | Non-RABV Lyssavirus | Rare | Bat-associated (Russian Far East) | [2]C |
| Skunk Exposure | Terrestrial Zoonosis | Regional | North Central Skunk variant | [65]C[69]D |
| Cat Exposure | Terrestrial Zoonosis | Occasional | Local geographic variants | [62]D |
| Aerosolization | Environmental | Rare | Laboratory or cave-associated | [66]C |
Pathophysiology
- ▸Rabies virus utilizes the Rabies Virus Glycoprotein (RVG) to bind to nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction for entry.
- ▸The virus travels to the CNS via dynein-mediated retrograde axonal transport, moving transsynaptically between neurons to reach the brain.
- ▸Pathogenicity is linked to strict neurotropism; mutations at glycoprotein residues R333 and N194 can shift tropism to astrocytes and reduce lethality.
The pathophysiology of rabies, caused by neurotropic viruses in the Lyssavirus genus, is characterized by a highly evolved mechanism of neural invasion that evades the host immune system while systematically dismantling central nervous system (CNS) function [80]D[82]D. Unlike many other viral encephalitides that reach the brain via the hematogenous route, rabies virus (RABV) utilizes a strictly neuroanatomic pathway, moving from the site of peripheral inoculation to the CNS through retrograde axonal transport [85]D[86]D.
Viral Entry and Receptor Binding
The process begins with the deposition of virus-laden saliva into muscle or subcutaneous tissue, typically via a bite from an infected reservoir such as a bat or carnivore [2]C. The Rabies Virus Glycoprotein (RVG) is the critical molecular mediator for host cell entry [81]D[97]D. RVG acts as a ligand for specific receptors at the neuromuscular junction, most notably the nicotinic acetylcholine receptor (nAChR) [81]D[84]D.
This binding is highly specific; the RVG29 polypeptide sequence is so effective at targeting neurons and crossing the blood-brain barrier (BBB) that it is frequently utilized in nanomedicine to deliver therapeutic agents to the brain [93]D[96]D. By binding to nAChR, the virus gains entry into peripheral motor neurons. While the virus may replicate locally in muscle tissue to increase the viral load, its primary objective is the sequestration within the nervous system, where it is shielded from circulating neutralizing antibodies [80]D[74]D.
Retrograde Axonal Transport
Once internalized into the peripheral nerve, the virus does not replicate extensively in the axon. Instead, it utilizes the host's internal transport machinery to travel toward the spinal cord [85]D.
Mechanism of Neural Ascent:
- Step 1: Internalization: The virus is endocytosed into a vesicle at the presynaptic terminal.
- Step 2: Dynein-Mediated Transport: The viral nucleocapsid interacts with dynein motor proteins, which move the virus along microtubules in a retrograde direction (toward the cell body) [86]D[94]D.
- Step 3: Transsynaptic Spread: Upon reaching the cell body in the dorsal root ganglion or the ventral horn of the spinal cord, the virus replicates and then moves across synapses to the next order of neurons [85]D[92]D.
This transsynaptic movement is so precise that modified, G-deleted rabies viruses are used in neuroscience to map "inputomes"—the complex network of monosynaptic connections to specific neurons [85]D[89]D. The virus effectively "jumps" from the postsynaptic to the presynaptic neuron, allowing it to ascend the spinal cord and reach the brainstem and limbic system [94]D[95]D.
CNS Replication and Neuronal Dysfunction
Upon reaching the brain, the virus undergoes rapid replication within the cytoplasm of neurons. A hallmark of this stage is the formation of Negri bodies, which are eosinophilic, sharply outlined neuronal cytoplasmic inclusions [99]C. These inclusions represent viral "factories" where nucleocapsid proteins and viral RNA are synthesized [99]C.
Despite the profound clinical symptoms, including psychomotor agitation, tremor, and dysphagia, the brain often shows surprisingly little gross structural damage or traditional inflammatory infiltration early in the infection [2]C[80]D. The virus causes death not through massive tissue necrosis, but through the disruption of essential neurotransmission and cellular homeostasis [88]D. For example, viral interference with ion channels and neurotransmitter receptors (such as GABAergic systems) leads to the characteristic autonomic instability and spasms [88]D.
Cellular Tropism and Immunogenetics
The standard wild-type rabies virus is strictly neurotropic. However, specific mutations in the glycoprotein can alter this tropism. Research into recombinant variants has shown that substitutions at positions R333 and N194 (e.g., R333E or N194S) can shift the virus from a neuronal-only infection to an astrocyte-restricted infection [82]D.
| Glycoprotein Mutation | Cellular Tropism | Clinical Outcome |
|---|---|---|
| Wild-type (R333/N194) | Strictly Neuronal | Fatal Encephalitis [2]C |
| SPBNGAK (R333E/N194K) | Mixed Neuronal/Astrocytic | Lethal Disease [82]D |
| TriGAS (R333E/N194S) | Astrocyte-Restricted | Reduced Pathogenicity; Immune Activation [82]D |
This tropism shift is significant because astrocyte-restricted infection often triggers a protective CNS immune response, whereas purely neuronal infection allows the virus to remain "invisible" to the immune system until it is too late for an effective response [82]D. Susceptibility to fatal disease is thus a balance between the virus's ability to maintain strict neurotropism and the host's ability to detect the viral glycoprotein before it reaches the higher cortical centers [74]D[82]D.
Centrifugal Spread
In the final stage of pathogenesis, the virus moves centrifugally (away from the CNS) via the cranial nerves and peripheral autonomic fibers [2]C. This allows the virus to reach highly innervated peripheral organs. The most critical site for transmission is the salivary glands, where the virus replicates in acinar cells and is shed into the saliva [2]C. This ensures that the host's aggressive behavior (driven by limbic system infection) and the high viral titer in the mouth coincide, facilitating transmission to the next host via a bite [2]C[80]D.
| Virus Variant | Primary Reservoir | Key Pathophysiologic Features |
|---|---|---|
| Rabies Virus (RABV) | Carnivores, Bats | Classic fatal encephalitis; Negri body formation [99]C |
| Irkut Virus (IRKV) | Bats | Psychomotor agitation, jaw tremors, and rapid fatal encephalitis [2]C |
| Tacaribe Virus (TCRV) | Bats | Often found in brain virome; used as a comparative non-rabies neurotropic model [11]D |
| Modified CVS-N2cΔG | Laboratory/Tracing | Optimized for high-efficiency transsynaptic transfer in inputome mapping [86]D |
Clinical Features
- ▸The hand is the most frequent site of rabies-transmitting bites, requiring careful anatomical and neurological inspection due to the high density of peripheral nerves [102].
- ▸Prodromal rabies is characterized by non-specific systemic signs such as significant weight loss and temperature fluctuations, alongside localized paresthesia at the exposure site [109, 112].
- ▸Clinical phenotypes are divided into 'furious' (80%) and 'paralytic' (20%), with the latter often misdiagnosed as other forms of ascending paralysis [106, 108].
The clinical presentation of rabies is a progressive, almost invariably fatal or . The history and physical examination must focus on identifying the exposure event, tracking the timeline of symptom evolution, and characterizing the specific neurological phenotype. Because the incubation period can be highly variable, a meticulous history of any mammalian contact is essential [106]D.
Presenting Symptoms
The clinical encounter typically begins with a history of a or scratch. The hand is the most common site for bite injuries, and because of the complex anatomy and proximity of nerves in the hand, even small wounds can facilitate viral entry into the peripheral nervous system [102]D. Clinicians must assess the competence of the host; small mammalian hosts (such as bats or small carnivores) are disproportionately more competent at transmitting rabies than larger hosts, often due to higher population densities and specific viral shedding patterns [103]D.
The Prodromal Phase
Following an incubation period that typically lasts weeks to months—though documented as 17 to 22 days in some animal models—patients enter the prodromal phase [112]D.
- Local Symptoms: The most pathognomonic early sign is paresthesia, pruritus, or pain at the site of the original wound, even if the wound has completely healed. This is thought to represent viral replication in the dorsal root ganglion.
- Systemic Signs: Patients often experience non-specific flu-like symptoms. Significant weight loss and fluctuations in body temperature are common early indicators of systemic involvement [106]D[109]D.
- Autonomic Changes: Early autonomic dysfunction may manifest as subtle changes in skin temperature, which can be detected via infrared thermography before overt neurological signs appear [112]D.
Neurological Examination Findings
As the virus ascends to the central nervous system, the examination findings diverge into two primary clinical patterns: the furious (encephalitic) form and the paralytic (dumb) form.
Motor and Sensory Assessment
In the furious form, patients exhibit episodic agitation, hypersalivation, and the classic sign of hydrophobia (involuntary pharyngeal spasms when attempting to drink). Between these episodes, the patient may appear relatively lucid. In contrast, the paralytic form presents with progressive muscle weakness starting near the bite site and ascending symmetrically or asymmetrically, mimicking . Unlike GBS, however, sensory involvement in paralytic rabies is usually minimal, and the progression is relentlessly downhill [106]D[108]D.
Cranial Nerve and Autonomic Evaluation
- Cranial Nerves: Examination may reveal pupillary abnormalities, facial weakness, or dysphagia.
- Autonomic System: This is a critical area of focus. Clinicians should monitor for hyperpyrexia, excessive sweating, and cardiac arrhythmias. In experimental models, a decrease in body temperature and significant weight loss are used as humane endpoints, signaling the transition to terminal disease [109]D.
Phenotypic Variants
The clinical presentation can vary based on the viral strain and host factors. For instance, mutations in the rabies virus G protein at position 333 (Arg or Lys) are known to determine high pathogenicity and lethal outcomes [105]D.
| Variant | Key Features | Frequency |
|---|---|---|
| Furious (Encephalitic) | Agitation, hydrophobia, aerophobia, autonomic instability, hallucinations. | ~80% |
| Paralytic (Dumb) | Ascending paralysis, relative sensory sparing, early bladder dysfunction, longer survival. | ~20% |
| Atypical | Seizures, focal motor deficits, or prolonged prodrome without classic hydrophobia. | Rare |
Red Flags
Certain findings necessitate immediate intensive care stabilization and indicate a transition to the terminal phase of the infection:
- Respiratory Compromise: Development of inspiratory muscle spasms or generalized paralysis leading to apnea.
- Autonomic Instability: Rapidly fluctuating blood pressure or heart rate, and hyperpyrexia [112]D.
- Rapid Weight Loss: In clinical and experimental settings, a loss of >10-15% of body weight is a marker of severe disease progression [109]D.
Atypical Presentations
Clinicians should remain vigilant for atypical cases where the classic bite history is missing or the symptoms are subtle. In some instances, the distribution of viral antigen in the brain does not strictly correlate with the clinical presentation, meaning a patient may lack classic "furious" signs despite significant cortical involvement [106]D. Furthermore, while dog bites are the most common source globally, bat-associated rabies may present more frequently with focal neurological deficits or myoclonus rather than hydrophobia [102]D[103]D.
Examination Protocol for Suspected Rabies
- Step 1: Inspect the site of the reported bite for healed scars, active infection, or localized paresthesia [102]D.
- Step 2: Perform a serial neurological exam every 4–6 hours to track the progression of weakness or agitation [106]D.
- Step 3: Monitor autonomic vitals, specifically looking for temperature spikes and signs of dehydration due to hydrophobia [112]D.
- Step 4: Assess for "red flag" symptoms, particularly respiratory effort and the ability to clear secretions [109]D.
| Feature | Furious Rabies | Paralytic Rabies |
|---|---|---|
| Primary Symptom | Agitation and Hyperactivity | Progressive Weakness |
| Hydrophobia | Present in nearly all cases | Usually absent |
| Consciousness | Fluctuating (lucid intervals) | Usually preserved until late |
| Survival Time | Shorter (days) | Longer (weeks) |
| Pathophysiology | Brainstem/Limbic involvement | Spinal cord/Peripheral nerve involvement [106]D |
Clinical Features and Variants
- ▸Rabies presents in two primary forms: Encephalitic (furious), characterized by agitation and hydrophobia, and Paralytic (dumb), which mimics Guillain-Barré Syndrome.
- ▸The prodromal phase often features localized pruritus or pain at the site of the original animal bite, even after the wound has healed.
- ▸Hydrophobia and aerophobia are pathognomonic signs resulting from the loss of brainstem inhibitory control over respiratory and swallowing reflexes.
Rabies is a near-fatal zoonotic disease characterized by acute, progressive encephalomyelitis [114]D[124]D. The clinical course is notoriously deceptive, beginning with a silent incubation period that typically lasts from a few weeks to several months [125]D. During this phase, the virus replicates at low levels in muscle tissue while evading the host immune response through multifunctional viral proteins [114]D[120]D. Once the virus enters the peripheral nerves and ascends to the central nervous system (CNS), the disease becomes irreversible and almost 100% fatal [113]D[120]D.
Presenting Symptoms
The clinical onset begins with a prodromal phase lasting 2–10 days. Patients often present with non-specific constitutional symptoms including fever, chest tightness, and shortness of breath [4]C[116]C[119]C. A highly suggestive early feature is paresthesia, pain, or intense pruritus at the site of the original exposure, even if the wound has long since healed [4]C[127]C. This occurs due to viral replication in the dorsal root ganglia corresponding to the bite site [115]D. As the virus spreads within the CNS, patients transition into one of two distinct clinical phenotypes: encephalitic (furious) or paralytic (dumb) rabies [115]D[132]C.
Neurological Examination Findings
When examining a suspected rabies patient, clinicians must systematically evaluate for signs of cortical dysfunction and autonomic instability.
1. Motor and Sensory Assessment: In the encephalitic form, patients exhibit profound agitation, combativeness, and hyperreactivity to stimuli [116]C. In contrast, the paralytic form presents with progressive motor weakness, often starting in the bitten limb and ascending symmetrically or asymmetrically [117]C[118]C. Sensory loss is less common than motor deficits, but urinary incontinence and limb numbness are frequently reported [118]C[119]C.
2. Cranial Nerve and Brainstem Evaluation: Cranial nerve involvement is a hallmark of advanced disease. Findings include:
- Ptosis and neck drop (often seen in paralytic variants) [129]C.
- Dysphagia and hypersalivation due to spasms of the pharyngeal and laryngeal muscles [3]C[126]C.
- Facial nerve palsy, particularly if the bite was located on the or neck [129]C.
3. Autonomic Instability: Patients often demonstrate "autonomic storms," characterized by episodes of palpitations, profuse sweating, and fluctuating blood pressure [119]C.
Examination Protocol for Suspected Rabies
To differentiate rabies from other encephalitides, the following bedside maneuvers should be performed:
- Step 1: Hydrophobia Provocation: Offer the patient a glass of water. In encephalitic rabies, the sight or sound of water triggers violent, involuntary spasms of the diaphragm and accessory respiratory muscles [116]C[131]C. This occurs because the virus disrupts brainstem inhibitory pathways [120]D.
- Step 2: Aerophobia Provocation: Fan a draft of air across the patient’s face. A positive response involves similar spasmodic gasping or agitation [116]C.
- Step 3: Assessment of Consciousness: Note that in early stages, patients may have "lucid intervals" where they are calm and cooperative between episodes of agitation [116]C.
Phenotypic Variants
While both forms result from the same virus, the clinical presentation differs based on the host's immune response and the specific neural pathways targeted [115]D[121]D.
| Feature | Encephalitic (Furious) Rabies | Paralytic (Dumb) Rabies |
|---|---|---|
| Frequency | ~80% of human cases [115]D | ~20% of human cases [115]D |
| Primary Symptoms | Agitation, confusion, hallucinations [116]C | Ascending paralysis, limb weakness [117]C[118]C |
| Pathognomonic Signs | Hydrophobia, aerophobia [131]C | Often absent; mimics GBS [117]C[132]C |
| Autonomic Signs | Hypersalivation, sweating, palpitations [119]C[126]C | Urinary incontinence, respiratory failure [118]C[119]C |
| Diagnostic Challenge | Usually recognized clinically [127]C | Frequently misdiagnosed as stroke or GBS [118]C[132]C |
Diagnosis and Workup
- ▸The Rapid Fluorescent Focus Inhibition Test (RFFIT) is the gold standard for measuring neutralizing antibodies, with a critical threshold of 0.5 IU/mL.
- ▸Antemortem diagnosis requires multiple samples (saliva, skin, CSF) because viral shedding is intermittent and tests may be negative in the first week.
- ▸Paralytic rabies is a frequent diagnostic pitfall as it closely mimics Guillain-Barré syndrome; EMG can help differentiate by showing denervation rather than demyelination.
The diagnosis of rabies presents a significant clinical challenge due to its near-universal fatality, diverse transmission routes, and marked clinical variability [66]C. While the classic encephalitic (furious) form is often recognized by pathognomonic signs like hydrophobia, the paralytic form can frequently be misdiagnosed as or other motor neuronopathies [117]C. Timely diagnosis is essential not only for patient but also for implementing public health measures and identifying potential exposures in others [137].
Diagnostic Criteria
Formal diagnosis requires a combination of clinical suspicion and laboratory confirmation. Because symptoms often appear only after the virus has reached the central nervous system (CNS), the window for antemortem diagnosis can be narrow [142]C.
- Required Features: Progressive acute encephalomyelitis or ascending paralysis [117]C.
- Supportive Features: History of animal bite or scratch (WHO Category II or III), hydrophobia (fear of water), aerophobia (fear of drafts), or localized paresthesia at the site of exposure [66]C[137].
- Exclusion Criteria: Identification of an alternative etiology (e.g., bacterial meningitis, ) or clinical recovery without intensive experimental intervention, as rabies is almost always fatal [142]C.
Laboratory Tests
Laboratory confirmation is the cornerstone of rabies diagnosis. Multiple samples (saliva, skin, CSF, and serum) should be collected to increase diagnostic yield, as viral shedding can be intermittent [141]D.
Molecular Techniques (RT-PCR)
While the fluorescent antibody test (FAT) remains the current WHO "gold standard" for postmortem brain tissue, molecular techniques like RT-PCR are increasingly advocated as the preferred antemortem method [141]D. RT-PCR offers high sensitivity and specificity, allowing for the detection of rabies virus (RABV) RNA in saliva, CSF, and nuchal skin biopsies [141]D. Recent advancements include lyophilized qRT-PCR reagents, which facilitate diagnosis in remote or resource-limited areas where maintaining a cold chain is difficult [148]D.
Serology and Neutralizing Antibodies
Serological testing measures rabies virus neutralizing antibodies (RVNAs). The Rapid Fluorescent Focus Inhibition Test (RFFIT) is the standard assay for quantifying these antibodies [147]D.
- Threshold of Protection: An RVNA concentration of 0.5 IU/mL is the internationally recognized threshold for a protective immune response [143]D.
- Clinical Utility: In unvaccinated individuals, the presence of any RVNA is diagnostic of infection. In vaccinated individuals, a four-fold rise in titer or very high levels in the CSF (where the blood-brain barrier usually restricts antibody entry) suggests active infection [139]D[144]D.
- Alternative Assays: Blocking ELISA methods have been developed for herd immunity monitoring but are generally less preferred than RFFIT for individual clinical diagnosis due to lower agreement with neutralization tests [151]D.
Direct Fluorescent Antibody (DFA) Test
The DFA (or FAT) test remains the definitive method for postmortem confirmation. It involves using fluorescently labeled antibodies to detect RABV nucleoprotein (N) antigens in brain smears (typically from the hippocampus or brainstem) [57]D[141]D. New assays, such as time-resolved fluoroimmunoassay (TRFIA), are also being developed to evaluate virus particle integrity by targeting the exposed nucleoprotein [150]D.
Imaging and Electrodiagnostic Studies
Imaging is primarily used to rule out other causes of encephalitis, as findings in rabies can be subtle or absent in the early stages [66]C.
- Magnetic Resonance Imaging (MRI): MRI is the modality of choice. Typical findings include T2-weighted or FLAIR hyperintensities in the brainstem, hippocampus, and gray matter [83]D[87]D. These findings reflect the virus's predilection for the limbic system and autonomic centers [91]D.
- Electrodiagnostic Studies (EMG/NCS): In the paralytic form, electromyography (EMG) may show evidence of widespread denervation and motor neuronopathy, which helps differentiate it from the demyelinating patterns seen in classic [117]C.
Diagnostic Algorithm
Step 1: Clinical Assessment Identify patients with acute progressive neurological symptoms and a history of animal exposure. Note that up to 20% of patients may not recall a specific exposure event [66]C.
Step 2: Initial Sample Collection Collect serial saliva samples (at least three, taken 3–6 hours apart), a nuchal skin biopsy (including hair follicles to capture cutaneous nerves), and serum [141]D.
Step 3: Molecular and Serological Testing Perform RT-PCR on saliva and skin. Order RFFIT on serum and CSF. If initial tests are negative but suspicion remains high, repeat testing in 24–48 hours [141]D[143]D.
Step 4: Advanced Diagnostics In cases with negative standard workups but high clinical suspicion, consider probe-capture metagenomics to identify viral RNA that may be missed by targeted primers [66]C.
| Test | Sample Type | Finding | Timing | Sensitivity/Specificity |
|---|---|---|---|---|
| RT-PCR | Saliva, Skin, CSF | RABV RNA detection | Early to late symptomatic | High sensitivity; preferred antemortem [141]D |
| DFA / FAT | Brain tissue (Postmortem) | Fluorescent viral antigens | Postmortem | 100% (Gold Standard postmortem) [57]D |
| RFFIT | Serum, CSF | RVNA ≥ 0.5 IU/mL | >7 days after symptoms | High specificity for infection in unvaccinated [143]D |
| Wound Swab PCR | Bite site | RABV RNA | <24 hours post-exposure | Useful for exposure confirmation [137] |
| MRI | Brain | T2/FLAIR hyperintensities | Mid-to-late stage | Low sensitivity; high utility for exclusion [66]C |
Diagnosis of Rabies
- ▸Antemortem diagnosis requires a combination of saliva RT-PCR, nuchal skin biopsy, and antibody testing in serum and CSF.
- ▸Sensitivity of diagnostic tests is low in the first few days of symptoms and increases over time; negative early tests do not rule out rabies.
- ▸Paralytic rabies can mimic Guillain-Barré syndrome, requiring electrodiagnostic studies to identify motor neuronopathy.
The diagnosis of rabies is exceptionally challenging due to its variable incubation period, which typically ranges from 20 to 90 days but can extend to over one year [160]C[161]C. Because the disease is near-universally fatal once symptoms appear, rapid and accurate diagnosis is critical for clinical and public health interventions, such as identifying other potentially exposed individuals [51]D[66]C. Diagnosis relies on a combination of clinical suspicion, detailed exposure history, and specialized laboratory testing, as routine blood work and neuroimaging are often non-specific [160]C[166]D.
Diagnostic Criteria
Formal diagnosis requires the presence of progressive neurological dysfunction combined with laboratory confirmation of the rabies virus (RABV) or other lyssaviruses [6]D[166]D.
- Required Features: Acute, progressive encephalitis or myelitis. Clinical signs include fever, psychomotor agitation, jaw tremors, aphasia, and dysphagia [2]C[160]C.
- Supportive Features: A history of animal exposure (e.g., dog, cat, or bat bites/scratches) is the strongest supportive evidence [161]C[162]D. Specific signs like hydrophobia (fear of water) or aerophobia (fear of drafts) are highly suggestive of the encephalitic (furious) form [160]C.
- Exclusion Criteria: Identification of an alternative etiology, such as bacterial meningitis, substance abuse, or other viral encephalitides (e.g., Japanese encephalitis), although these must be ruled out concurrently with rabies testing [159]D[160]C.
Laboratory Tests
Antemortem diagnosis requires testing multiple specimens because viral shedding is intermittent and may be absent early in the disease course [166]D.
- Saliva (RT-PCR): This is often the most sensitive antemortem test. It detects viral RNA shed from the salivary glands. Sensitivity increases as the disease progresses, often reaching peak levels after the first week of symptoms [166]D.
- Nuchal Skin Biopsy (DFA or RT-PCR): A full-thickness skin biopsy (3–5 mm) from the posterior neck at the hairline is performed. This test looks for rabies antigen or RNA within the cutaneous nerves surrounding hair follicles, where the virus travels via retrograde axonal transport [166]D.
- Serum and CSF (Antibody Testing): Indirect fluorescent antibody (IFA) or virus neutralization tests can detect antibodies. However, these are only diagnostic in patients who have not previously received rabies vaccination or rabies immunoglobulin (RIG) [166]D. Antibodies in the CSF are highly specific for rabies encephalitis regardless of vaccination history [166]D.
- Metagenomics: Newer techniques like probe-capture metagenomics are emerging as powerful tools for identifying RABV in cases with no known exposure history [66]C.
Imaging
Neuroimaging is primarily used to exclude other causes of acute encephalitis. Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) of the brain are frequently normal during the early stages of infection [160]C. As the disease progresses, MRI may show non-specific hyperintensities in the gray matter, brainstem, or hippocampus, reflecting the neurotropic nature of the virus [160]C.
Electrodiagnostic Studies
Electrodiagnostic testing is vital for differentiating the paralytic (dumb) form of rabies from (GBS) [117]C. While GBS typically presents with demyelinating or axonal polyneuropathy, paralytic rabies often shows evidence of severe motor neuronopathy. Electromyography (EMG) may reveal widespread fasciculations and denervation potentials, indicating direct viral involvement of the spinal cord and peripheral nerves [117]C.
Diagnostic Algorithm
Clinicians should follow a systematic approach when rabies is suspected, especially in endemic regions or following high-risk animal contact [161]C[164]D.
- Step 1: Clinical Assessment: Evaluate for prodromal symptoms (fever, malaise) followed by neurological signs (agitation, dysphagia, or ascending paralysis) [2]C[160]C.
- Step 2: Exposure History: Inquire about bites, scratches, or contact with bats, dogs, or wild mammals within the last year [155][162]D.
- Step 3: Initial Antemortem Sampling: Simultaneously collect saliva (3 samples, 3–5 hours apart), a nuchal skin biopsy, serum, and CSF [166]D.
- Step 4: Repeat Testing: If initial tests are negative but clinical suspicion remains high, repeat saliva and skin testing, as findings may be normal in the first week of illness [166]D.
- Step 5: Post-mortem Confirmation: If the patient expires, the gold standard for diagnosis is the Direct Fluorescent Antibody (DFA) test on fresh brain tissue (specifically the medulla, cerebellum, and hippocampus) [3]C[172]C.
| Test Type | Specimen | Finding | Sensitivity (Early) | Specificity |
|---|---|---|---|---|
| RT-PCR | Saliva | Viral RNA | Moderate (increases over time) | High [166]D |
| DFA | Nuchal Skin | Viral Antigen in nerves | Moderate | High [166]D |
| Antibody (IFA) | Serum | IgG/IgM (unvaccinated) | Low in 1st week | High [166]D |
| Antibody (IFA) | CSF | IgG/IgM | Low in 1st week | Very High [166]D |
| DFA (Gold Std) | Brain Tissue | Negri bodies/Antigen | N/A (Post-mortem) | 100% [172]C |
Management of Rabies
- ▸Post-exposure prophylaxis (PEP) must be initiated within 24 hours of Category III exposure to be effective, as clinical rabies is nearly 100% fatal.
- ▸Passive immunization with HRIG (20 IU/kg) or RmAb (0.3 mg/kg) should be infiltrated directly into the wound site to neutralize the virus locally.
- ▸The target threshold for protection is a rabies virus neutralizing antibody (RVNA) titer of ≥0.5 IU/mL.
The of rabies is divided into two distinct clinical phases: the prevention of disease through post-exposure prophylaxis (PEP) following a suspected exposure, and the supportive care of patients who have already developed clinical symptoms. Rabies is almost invariably fatal once neurological symptoms appear [174][181]D. Therefore, the primary goal of clinical management is the rapid administration of PEP to prevent the virus from entering the central nervous system (CNS) [51]D[161]C.
Step 1: Initial Assessment and Severity Classification
Immediate assessment must determine the category of exposure and the patient's prior vaccination status. Clinical management is dictated by the WHO exposure categories:
- Category I: Touching or feeding animals, licks on intact skin (No PEP required).
- Category II: Nibbling of uncovered skin, minor scratches or abrasions without bleeding (Immediate vaccination required).
- Category III: Single or multiple transdermal bites or scratches, licks on broken skin, or contamination of mucous membranes with saliva from licks. This also includes direct contact with bats [184]D.
Clinicians must decide on disposition based on the severity of the wound and the risk of the biting animal. Patients with Category III exposures, especially those involving the face, neck, or hands, require immediate intensive PEP within 24 hours [174][189]D. Delays in seeking medical attention or reporting encounters (e.g., bat exposures) are major drivers of treatment failure and death [184]D[189]D.
Step 2: Passive Immunization (RIG or RmAb)
For Category III exposures, passive immunization provides immediate neutralizing antibodies before the patient’s immune system can respond to the vaccine.
Administer Human Rabies Immunoglobulin (HRIG) at 20 IU/kg or Rabies Monoclonal Antibodies (RmAb) at 0.3 mg/kg [35]. The agent should be infiltrated as much as possible into and around the wound site [35]. Monoclonal antibodies like Zamerovimab, Mazorelvimab, or Rabishield are increasingly used as they are non-inferior to HRIG in achieving rabies virus neutralizing antibody (RVNA) titers ≥0.5 IU/mL by day 7 [35][174]. New delivery methods, such as bilayer microneedle patches containing HRIG and tazarotene, are being developed to improve wound healing and provide a less invasive alternative to traditional injections [181]D.
Step 3: Active Immunization (Vaccine)
Active immunization must be initiated simultaneously with passive immunization but at a different anatomical site to avoid interference.
Administer Rabies Vaccine (Essen regimen or abbreviated 1-week protocol) [175][185]D. The Essen regimen typically involves intramuscular injections on days 0, 3, 7, 14, and 28. However, an abbreviated one-week intradermal (ID) regimen (two-site ID on days 0, 3, and 7) has shown adequate seroconversion (RVNA ≥0.5 IU/mL) by day 14 in healthy individuals and healthcare workers [175]. In immunocompromised patients, serological testing is essential to confirm an adequate immune response, as they may require altered schedules [139]D.
Step 4: Management of Symptomatic Rabies
If a patient presents with clinical symptoms—such as progressive lower extremity pain, hypersalivation, dysphagia, agitation, or hydrophobia—management shifts to aggressive supportive care or palliation [177]C.
- Isolation and Sedation: Patients should be placed in a quiet, low-stimulus environment. Use benzodiazepines or antipsychotics to manage agitation and spasms [177]C.
- Airway Management: is often required as the disease progresses to respiratory failure [177]C.
- Cardiac Support: Monitor for and arrhythmias, which are common clinical features in the terminal phase [64]C.
Despite intensive care, clinical rabies remains nearly 100% fatal [51]D[181]D. Case reports indicate that even with early consideration of the diagnosis, the rapid progression of neurological deterioration often outpaces diagnostic confirmation and experimental interventions [177]C.
Step 5: Resolution and Public Health Transition
In the event of a patient's death, post-mortem brain biopsy is the gold standard for confirmation [64]C. Management then transitions to a public health investigation to identify and provide PEP to all potentially exposed contacts, including family members and healthcare workers who may have had contact with the patient's saliva or mucous membranes [64]C[65]C. Human-to-human transmission has also been documented via solid organ transplantation, necessitating rigorous donor screening for any history of animal bites (e.g., skunks or bats) [65]C.
Experimental Approaches and Future Directions
Research is focused on bypassing the blood-brain barrier to deliver therapeutics directly to the CNS. Rabies virus glycoprotein (RVG) peptides are being utilized as cell-penetrating peptides (CPPs) to transport cargo, such as nanorobots or nanocages, into neurons [84]D[187]D. For example, RVG29-anchored nanocages have been engineered to target nicotinic acetylcholine receptors (nAChRs) for precise intracellular delivery [70]D[187]D. While currently studied for other neurological conditions, these biomimetic platforms represent the future of targeted rabies therapy [84]D.
| Agent | Dose | Route | Mechanism | Evidence Level |
|---|---|---|---|---|
| Human Rabies Immunoglobulin (HRIG) | 20 IU/kg | Local infiltration/IM | Polyclonal antibodies from human donors | 1b [35] |
| Zamerovimab / Mazorelvimab | 0.3 mg/kg | Local infiltration/IM | Recombinant monoclonal antibodies | 1b [35] |
| Rabishield (RmAb) | Standard dose | Local infiltration/IM | Monoclonal antibody (SII RMAb) | 1b [174] |
| Microneedle Patch | Experimental | Transdermal | Bilayer HA/PVP patch for HRIG delivery | 5 [181]D |
Supportive Care and Complication Management
- ▸Symptomatic rabies is virtually 100% fatal, making compassionate palliative care the primary clinical imperative.
- ▸Aggressive wound irrigation and debridement are essential to prevent secondary bacterial sepsis from polymicrobial animal flora.
- ▸Heavy sedation with benzodiazepines is required to manage the extreme agitation and painful spasms of furious rabies.
The of symptomatic rabies is a clinical challenge characterized by a near-100% fatality rate once neurological symptoms manifest [203]D[207]D. Clinical care focuses on two parallel tracks: aggressive supportive care for those undergoing experimental intensive protocols and, more commonly, comprehensive palliative care to ensure a dignified, pain-free death [203]D[208]D. Because the disease progresses through stages of extreme agitation, autonomic instability, and eventual respiratory failure, the clinician must prioritize symptom control and the prevention of secondary complications [195]D[208]D.
Step 1: Initial Assessment and Severity Classification
Upon presentation with suspected rabies encephalomyelitis, the patient must be immediately isolated in a quiet, low-stimulus environment to prevent triggering spasms or seizures [203]D[208]D.
- Classification: Differentiate between furious rabies (characterized by agitation, hydrophobia, and aerophobia) and paralytic rabies (characterized by ascending paralysis resembling Guillain-Barré syndrome) [203]D.
- Disposition: Patients with acute neurological symptoms require ICU admission for airway protection and autonomic monitoring [197]D[208]D. If intensive care is unavailable or deemed futile, transition to a dedicated palliative unit is mandatory [203]D.
- Wound Assessment: Evaluate the primary bite site for secondary bacterial infection. Wild animal attacks often involve complex forces (crushing, tearing) that devitalize tissue and introduce polymicrobial flora [155][212]D.
Step 2: Wound Management and Infection Control
Immediate and aggressive local treatment is the most effective way to reduce the viral load and prevent secondary sepsis [192]D[198]D.
- Irrigation: Perform high-pressure irrigation with 0.9% normal saline or sterile water to remove debris and microscopic infectious agents [192]D[213]D.
- Debridement: Selectively debride devitalized tissue, especially in complex maxillofacial injuries common in children [204]C[212]D[213]D.
- Antibiotic Prophylaxis: Administer Amoxicillin-clavulanate 875/125 mg orally twice daily (or pediatric equivalent 25-45 mg/kg/day) for 3-5 days for high-risk wounds (e.g., hand, face, or immunocompromised patients) [193]D[198]D[202]D. This targets Pasteurella, Capnocytophaga, and anaerobic oral flora [193]D[194]D.
Step 3: Management of Neurological and Autonomic Instability
Autonomic dysfunction is a hallmark of lyssavirus infection, manifesting as heart rate variability, hyperthermia, and orthostatic hypotension [195]D.
- Seizure Control: Administer Diazepam 5-10 mg IV (slow bolus) every 4-6 hours as needed to control muscular spasms and seizures [208]D.
- Sedation: For extreme agitation or hydrophobia, use a Midazolam infusion at 1-5 mg/hr to maintain a calm state [208]D.
- Fever Management: Maintain core temperature below 38.5°C using Paracetamol 1g IV or PR every 6 hours to reduce metabolic demand and cerebral edema [208]D.
Step 4: Monitoring and Titration
Continuous monitoring is required to manage the rapid fluctuations in clinical status [197]D.
- Hydration: Maintain euvolemia with isotonic crystalloids. Avoid overhydration, which may exacerbate cerebral edema [208]D.
- Airway: Monitor for inspiratory muscle spasms. While mechanical ventilation can prolong life, it does not alter the outcome in the absence of a cleared infection and may prolong the dying process [203]D[208]D.
- Neurological Checks: Monitor for signs of Acute Demyelinating Encephalomyelitis (ADEM), particularly in regions still using older nervous tissue-derived vaccines, which are associated with high neurotoxicity [201]C[210]C.
Step 5: Palliative Transition and Resolution
When the diagnosis is confirmed and the patient enters the terminal phase (respiratory failure or coma), the focus must shift entirely to palliation [203]D.
- Symptom Relief: Ensure the patient is never left alone. Use heavy sedation (e.g., Midazolam or Haloperidol) to eliminate the terror associated with hydrophobia [203]D[208]D.
- Family Support: Provide psychological support and ensure the family understands that the patient is not infectious through casual contact, though barrier precautions for secretions are necessary [203]D[208]D.
- Organ Donation: Note that rabies can be transmitted via organ transplantation (e.g., kidney); therefore, symptomatic patients or those with unexplained encephalitis are strictly contraindicated as donors [191].
| Drug | Dose | Route | Indication | Evidence Level |
|---|---|---|---|---|
| Amoxicillin-clavulanate | 875/125 mg BID | PO | Secondary infection prophylaxis | 5 [193]D[202]D |
| Diazepam | 5-10 mg | IV/PR | Spasms and seizure control | 5 [208]D |
| Midazolam | 1-5 mg/hr | IV Infusion | Agitation and sedation | 5 [208]D |
| Paracetamol | 1 g | IV/PR | Hyperthermia management | 5 [208]D |
| Ceftriaxone | 1-2 g QD | IV | Severe bite-related cellulitis | 2a [155] |
Prognosis and Long-term Outcomes
- ▸Rabies is nearly 100% fatal once clinical symptoms manifest, with approximately 59,000 deaths annually worldwide.
- ▸Survival is exceptionally rare and is almost always associated with severe, permanent neurological deficits and the presence of early neutralizing antibodies.
- ▸The timeline from symptom onset to brain death typically ranges from 2 to 5 weeks, though atypical presentations can complicate the clinical picture.
The prognosis for clinical rabies is among the most dire in infectious medicine. Once the rabies virus (RABV) enters the central nervous system (CNS) and clinical symptoms manifest, the disease is considered almost 100% fatal [216], [221]D. Despite significant advances in critical care and experimental protocols, the global burden remains staggering, with approximately 59,000 human deaths occurring annually [221]D, [223]D. The nearly universal mortality rate is attributed to the virus's unique ability to evade the host immune system during its transit through the peripheral nerves and its subsequent devastating impact on the CNS microenvironment [63]D, [221]D.
Survival and Recovery Statistics
True survival from rabies is exceptionally rare, with only a few cases documented in medical literature [142]C. In the vast majority of these rare instances, survivors were individuals who had received some form of pre-exposure or post-exposure prophylaxis (PEP) prior to the onset of symptoms, which likely allowed for the early development of rabies virus neutralizing antibodies (RVNA) [142]C.
- Overall Mortality: ~100% once clinical signs appear [51]D, [221]D.
- Full Recovery: Virtually 0%; almost all survivors exhibit permanent neurological deficits [142]C.
- Residual Deficits: >90% of the rare survivors suffer from profound neurological impairment, including cognitive decline, motor dysfunction, and sensory loss [142]C.
Timeline of Clinical Progression
The transition from the prodromal phase to death is typically rapid, though modern intensive care can prolong the physiological process. The incubation period is highly variable, but once neurological symptoms begin, the trajectory toward brain death is often measured in days or weeks [225]D.
- Prodromal Phase (Days 1–4): Initial non-specific symptoms such as fever, headache, or paresthesia at the bite site.
- Neurological Phase (Days 5–20): Development of encephalitic (furious) or paralytic (dumb) rabies. Atypical presentations, such as urinary symptoms, can delay diagnosis [225]D.
- Coma and Death (Days 20–35): Progression to autonomic instability and brain death. In one documented case, brain death occurred 28 days after the onset of neurological symptoms and 34 days after the very first atypical symptoms [225]D.
Prognostic Factors
Because there is no established cure for clinical rabies, prognostic factors primarily distinguish between a rapid demise and the remote possibility of survival with experimental intervention. The presence of early host-derived RVNAs is the most significant indicator of a potential (though still unlikely) survival outcome [142]C.
| Factor | Favorable for Survival (Rare) | Poor Prognosis |
|---|---|---|
| Vaccination Status | Prior pre-exposure vaccination or partial PEP [142]C | No prior vaccination or PEP [225]D |
| Antibody Response | Early detection of RVNA in serum/CSF [142]C | Absence of RVNA at symptom onset [142]C |
| Bite Location | Distal extremities (e.g., feet) [214] | , neck, or highly innervated areas [214] |
| Viral Load | Low inoculum (e.g., minor scratch) | High inoculum (e.g., deep Category III tears) [133] |
| Virus Strain | Certain bat-derived variants (anecdotal) | Highly neurotropic canine variants [217]C |
Long-term Sequelae
For the few individuals who survive the acute infection, the "recovery" is often a misnomer. The virus causes irreversible damage to the blood-brain barrier and neuronal architecture [63]D. Long-term outcomes for survivors include:
- Neurological Impairment: Severe ataxia, hemiparesis, or quadriparesis due to extensive CNS inflammation [142]C.
- Cognitive and Psychological Impact: Survivors often remain in a vegetative or minimally conscious state; those with higher function report profound fatigue, chronic pain, and significant psychological trauma [142]C.
- Secondary Complications: Survivors are at high risk for recurrent pneumonia, pressure ulcers, and autonomic dysfunction [155].
Recurrence and Reinfection
There is no evidence of "recurrence" in the traditional sense, as the primary infection is almost always terminal. However, immunity following natural infection is not well-characterized due to the lack of survivors. Prevention remains the only viable strategy; modern vaccines, such as the Vero cell-based lyophilized vaccines, provide robust immunogenicity when administered via the Essen (5-dose) or Zagreb (4-dose) regimens [134]. Experimental mRNA and self-amplifying RNA (saRNA) vaccines are currently being studied to provide even more rapid and complete protection in a single dose, which could further improve the prognosis of exposed individuals in resource-limited settings [223]D, [224]D.
| Factor | Good Prognosis (Prevention) | Poor Prognosis (Clinical Disease) |
|---|---|---|
| PEP Timing | Immediate administration post-exposure | Delayed or no administration [225]D |
| Wound Care | Thorough washing and infiltration with RIG/mAbs [133], [145]D | Neglected wound care [217]C |
| Clinical Stage | Asymptomatic (Incubation) | Symptomatic (Encephalitic/Paralytic) [221]D |
| Immune Response | Rapid RVNA production >0.5 IU/mL [134] | Failure to mount early antibody response [142]C |
Special Populations
- ▸Rabies PEP is mandatory in all special populations, including pregnancy, as the disease is 100% fatal once symptoms appear.
- ▸Immunocompromised individuals require RIG infiltration even for Category II exposures, which normally only require vaccination in healthy patients.
- ▸Pediatric patients are at higher risk for head and neck bites, necessitating immediate RmAb or RIG infiltration and aggressive wound care.
The of rabies exposure in special populations requires nuanced clinical judgment, as the nearly 100% case fatality rate of the disease necessitates that post-exposure prophylaxis (PEP) never be withheld [51]D[174]. While the core principles of wound care and immunization remain constant, physiological differences in children, altered immune states, and the risks of pregnancy require specific modifications to standard protocols to ensure both safety and efficacy.
Pediatrics
Children represent a disproportionately high-risk group for rabies due to their shorter stature, which increases the likelihood of bites to the face, neck, and —areas with high nerve density that facilitate rapid viral transit to the central nervous system [174][227]. Furthermore, children may not always report minor exposures, leading to delayed treatment [184]D.
Diagnostic and Clinical Considerations: Pediatric dog bites are often associated with atypical bacterial species and high infection rates, requiring aggressive wound management [227]. In cases of Category III exposure (transdermal bites or scratches), the use of rabies monoclonal antibodies (RmAb) such as Rabishield has been shown to be safe and effective in children as young as 2 years old [174].
Treatment Modifications:
- Wound Management: Immediate and thorough irrigation with soap and water is the first line of defense [227].
- Vaccination Regimens: The standard 4-dose Essen regimen or the 3-session intradermal (ID) PEP (administered on days 0, 3, and 7) is immunogenic in pediatric populations [234]D. For pre-exposure prophylaxis (PrEP), a 2-dose ID regimen (0.1 mL at two sites on days 0 and 7) is safe and provides adequate seroconversion in immunocompetent children [237]D.
- Passive Immunization: Rabies immunoglobulin (RIG) or RmAb (e.g., SYN023 at 0.3 mg/kg) must be infiltrated into and around all wound sites [133][230].
Pregnancy and
Pregnancy is not a contraindication to rabies PEP. Because rabies is a fatal encephalitis, the benefits of vaccination and RIG administration always outweigh the theoretical risks to the fetus [174].
Safety and Teratogenicity: Modern cell-culture vaccines, including purified Vero cell rabies vaccines (PVRV) and human diploid cell vaccines (HDCV), have shown high safety profiles in clinical trials [32][228]. There is no evidence of teratogenicity associated with these inactivated vaccines [134].
Clinical Management:
- Delivery Planning: Rabies exposure does not necessitate a change in the mode of delivery unless the mother has already developed clinical symptoms of rabies.
- Breastfeeding: Breastfeeding is considered safe following the administration of rabies vaccines and RIG, as these products do not contain live virus and do not pose a risk of transmission to the infant [228].
Immunocompromised Individuals
Patients with primary or secondary immunodeficiencies (e.g., HIV/AIDS, malignancy, or those on immunosuppressive therapy) may exhibit an impaired or delayed immune response to the rabies vaccine [139]D.
Modified Protocols:
- Category II Exposure: Unlike immunocompetent patients who only require vaccination for Category II exposures, immunocompromised individuals must receive RIG infiltration in addition to the full vaccine series [145]D.
- Serological Monitoring: Post-vaccination serology is essential. The rabies virus neutralizing antibody (RVNA) concentration must reach ≥0.5 IU/mL to be considered protective [139]D[230]. If titers are inadequate, additional vaccine doses may be required.
- PrEP Considerations: In children on immunosuppressant therapy, a 2-dose ID PrEP regimen may result in lower RVNA titers compared to healthy peers, though most still achieve the 0.5 IU/mL threshold [237]D. For adults who received PrEP while immunocompetent, "boostability" (the ability to mount a rapid response to a booster) is generally maintained even after starting immunosuppressive monotherapy [236]D.
Elderly Populations
Older adults (aged >60 years) are at continued risk for rabies, particularly in regions with limited access to healthcare [51]D. While clinical trials for newer vaccines like PVRV-NG2 and lyophilized human diploid cell vaccines have demonstrated safety in adults up to age 60, data for the very elderly remain more limited [32][228].
Clinical Considerations:
- Comorbidities: Management must account for potential interactions with medications for chronic conditions. However, PEP should never be delayed for these reasons [174].
- Immune Senescence: Similar to the immunocompromised, elderly patients may have a slower immune response. While standard Essen (5-dose) or Zagreb (4-dose) regimens are typically used, clinicians should maintain a high index of suspicion for treatment failure if the exposure was severe [134][136].
| Population | Vaccine Regimen | Passive Immunization (RIG/mAb) | Special Considerations |
|---|---|---|---|
| Pediatrics | Essen or 3-session ID [234]D | Required for Cat III; dose-adjusted [174] | High risk of head/neck bites [227] |
| Pregnancy | Standard Essen or Zagreb [32] | Required for Cat III | No evidence of teratogenicity [134] |
| Immunocompromised | Standard series + Serology [139]D | Required for Cat II and III [145]D | RVNA must be ≥0.5 IU/mL [230] |
| Elderly | Standard Essen or Zagreb [136] | Required for Cat III | Monitor for immune senescence [51]D |
Prevention and Screening
- ▸Mass dog vaccination must reach a threshold of ≥ 70% coverage to establish herd immunity and interrupt transmission to humans [245].
- ▸Post-exposure prophylaxis (PEP) is highly effective but requires strict adherence to multi-dose schedules; non-compliance is a major driver of preventable rabies deaths [185, 243].
- ▸A One Health approach, integrating human PEP with wildlife and domestic animal surveillance, is essential for regional elimination [37, 183].
Rabies is a nearly 100% fatal zoonotic disease, making prevention the only viable strategy for survival [239]D. Because clinical symptoms signify an irreversible progression toward death, public health efforts focus on a "One Health" framework that integrates animal vaccination, human post-exposure prophylaxis (PEP), and robust environmental surveillance [37]D[241]D. Global initiatives, such as the "Zero by 30" goal, aim to eliminate dog-mediated human rabies deaths by 2030 through these multi-sectoral interventions [185]D.
Primary Prevention: Animal Reservoirs and One Health
The most effective method for preventing human rabies is the elimination of the virus at its source: domestic and wild animal populations. Mass dog vaccination (MDV) is the cornerstone of this effort, as domestic dogs are responsible for over 95% of human rabies deaths globally [245]D.
- Herd Immunity Thresholds: To effectively interrupt the transmission cycle between dogs and humans, vaccination campaigns must achieve a coverage rate of ≥ 70% [245]D. Achieving this in high-risk areas, such as refugee camps or peri-urban settlements, requires structured, rapid-response campaigns [38]D.
- Oral Rabies Vaccination (ORV): In populations where dogs are free-roaming or difficult to capture for injectable vaccines, ORV serves as a critical complementary tool [176]D. ORV has also been successfully deployed in wildlife "Border Maintenance Zones" to prevent the spread of rabies from reservoirs like coyotes, foxes, and raccoons, providing a benefit-cost ratio consistently above 1.0 by avoiding human healthcare expenditures [180]D.
- Emerging Reservoirs: While dogs remain the primary focus, cats are increasingly recognized as "bridge hosts" between wildlife and humans [242]D. Surveillance data indicates that cats are often the most common source of animal-induced injuries in certain urban settings, yet they are frequently excluded from systematic vaccination mandates [162]D[242]D.
Secondary Prevention: Post-Exposure Prophylaxis (PEP)
Secondary prevention involves the immediate administration of PEP following a suspected exposure (e.g., bite or scratch from a potentially rabid animal). The efficacy of PEP is time-dependent; delays or incomplete adherence to the vaccination schedule are the primary drivers of PEP failure [39]D[185]D.
PEP Protocol for Category II and III Exposures
- Wound : Immediate and thorough washing of all bite wounds and scratches with soap and water for at least 15 minutes. This mechanical action significantly reduces the viral load at the site of entry [39]D.
- Risk Assessment: Evaluate the animal's species, behavior, and vaccination status. In endemic regions, any unprovoked attack by a stray animal is treated as a high-risk exposure [244]D[247]D.
- Vaccination Schedule: Administration of a modern cell-culture vaccine (e.g., MRC-5 human diploid cell vaccine). Current guidelines support both 4-dose and 5-dose intramuscular schedules [250]D.
- Passive Immunization: For Category III exposures (transdermal bites or scratches), Rabies Immunoglobulin (RIG) must be infiltrated into and around the wound to provide immediate neutralizing antibodies while the patient's immune system responds to the vaccine [181]D[243]D.
Screening and Surveillance Recommendations
Screening for rabies does not involve traditional asymptomatic testing in humans but rather the systematic surveillance of animal-bite incidents and the monitoring of high-risk populations.
- Spatio-Temporal Mapping: Public health authorities use Global Moran’s I and Getis–Ord Gi* statistics to identify geographic "hotspots" where animal bites and laboratory-confirmed rabies cases cluster [244]D. This allows for targeted resource allocation and "ring vaccination" in response to outbreaks [241]D.
- High-Risk Groups: Screening and education efforts should prioritize children (who account for a large share of global exposures), migrants, and workers in rural or pastoralist communities where human-animal interactions are frequent [162]D[247]D[248]D.
- Animal Observation: In cases involving healthy domestic dogs or cats, a 10-day observation period is recommended. If the animal remains healthy, PEP can be discontinued, as the virus is only present in saliva during the clinical stage of the disease [247]D.
Vaccine Considerations and Emerging Technologies
Currently approved human rabies vaccines are inactivated, adjuvant-free formulations [239]D. While safe, they often require multiple doses, which can lead to poor patient compliance in resource-limited settings [239]D[243]D.
- Adverse Events: Common reactions include local pain, redness, and swelling. Multivariate analysis has identified previous history of allergies as a risk factor for adverse events, though the benefit of vaccination far outweighs the risk given the disease's fatality rate [40]D.
- Innovation in Delivery: To improve compliance, researchers are developing bilayer microneedle (MN) patches for the rapid, painless delivery of HRIG and vaccines [181]D. Additionally, novel mRNA and lipid nanoparticle (LNP) vaccines are being engineered to enhance immunogenicity and simplify dosing schedules [224]D[239]D.
- Veterinary Practice: In canine vaccination, studies have shown that needle replacement after vial puncture does not significantly affect the animal's physiological response or the injector's ease of administration, suggesting that standard protocols remain effective without unnecessary complexity [178].
| Schedule Type | Dosing Days | Rationale/Evidence |
|---|---|---|
| 5-Dose (Essen) | 0, 3, 7, 14, 28 | Traditional standard; provides robust long-term immunity [250]D. |
| 4-Dose (Zagreb) | 0 (2 doses), 7, 21 | Abridged schedule; non-inferior to 5-dose in immunogenicity and safety [250]D. |
| PrEP (Pre-exposure) | 0, 7, 21 or 28 | Recommended for high-risk professionals (vets, lab workers) [239]D. |
| Strategy | Description | Utility |
|---|---|---|
| Capture-Vaccinate-Release (CVR) | Teams catch and vaccinate free-roaming dogs. | Standard for high-density urban areas [245]D. |
| Roaming Static Point (RSP) | Owners bring dogs to a fixed vaccination station. | Cost-effective; relies on community participation [245]D. |
| Oral Rabies Vaccination (ORV) | Edible baits containing vaccine are distributed. | Essential for inaccessible or aggressive dog populations [176]D[183]D. |
Guidelines and Resources
- ▸The WHO recommends a shortened 3-session intradermal PEP regimen and a 2-dose PrEP regimen to improve global accessibility and cost-effectiveness.
- ▸Anti-rabies monoclonal antibodies (RmAbs) are now recognized as safe, non-inferior alternatives to human rabies immunoglobulin (HRIG) for Category III exposures.
- ▸The 'Zero by 30' initiative focuses on mass dog vaccination and a One Health approach to eliminate dog-mediated human rabies deaths by 2030.
The and prevention of rabies are governed by international standards established by the World Health Organization (WHO) and national bodies such as the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC). Current guidelines focus on achieving the "Zero by 30" global goal—eliminating dog-mediated human rabies deaths by 2030 [254][261]D. These frameworks emphasize a approach, integrating human, animal, and environmental surveillance to manage zoonotic spillover [258]D[267]D.
International and National Guidelines
Global rabies prevention strategies have shifted toward shortened, more cost-effective regimens to improve compliance and accessibility in high-burden regions. The WHO and ACIP provide the primary frameworks for post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP), though they occasionally differ in their recommended intramuscular (IM) and intradermal (ID) schedules [231][262]D.
| Guideline | Organization | Year | Key Recommendations |
|---|---|---|---|
| WHO Rabies Position Paper | WHO | 2018 (Updated) | Recommends shortened 3-session ID PEP; 2-dose ID PrEP; endorses monoclonal antibodies (mAbs) as alternatives to RIG [234]D[237]D[259]D. |
| ACIP Rabies Recommendations | CDC/ACIP | 2024 (Updated) | Recommends 4-dose Essen IM regimen for PEP in immunocompetent individuals; emphasizes bat exposure risk assessment [231][184]D. |
| One Health Zoonotic Disease Prioritization | CDC/Vietnam/China | 2024-2025 | Prioritizes rabies for multisectoral collaboration; emphasizes mass dog vaccination (MDV) to stop circulation [258]D[261]D. |
| Laboratory Diagnosis Standards | WHO/CDC | 2025 | Fluorescent antibody test (FAT) remains the postmortem gold standard, but molecular methods (PCR) are advocated for increased sensitivity [141]D. |
Post-Exposure Prophylaxis (PEP) Protocols
Modern PEP guidelines are designed to prevent viral entry into the central nervous system through three pillars: wound cleansing, vaccination, and passive immunization. A significant update in recent guidelines is the endorsement of anti-rabies monoclonal antibodies (RmAbs), such as ormutivimab, which have demonstrated non-inferiority to human rabies immunoglobulin (HRIG) [252]. RmAbs offer advantages in terms of standardized production, safety, and lower risk of blood-borne pathogen transmission [259]D.
Protocol for Category III Exposure Management
- Immediate Wound Care: Thoroughly wash all wounds with soap and water for at least 15 minutes. This mechanical action is critical for reducing viral load [259]D.
- Passive Immunization: Administer HRIG or RmAbs (e.g., ormutivimab) directly into and around the wound site on Day 0. If the calculated dose is insufficient to infiltrate all wounds, it should be diluted in sterile saline [252].
- Active Immunization: Initiate the vaccine series. The WHO-recommended shortened ID regimen (2 sites on days 0, 3, and 7) is increasingly used to reduce costs and visits [234]D. Alternatively, the 4-dose Essen IM regimen (days 0, 3, 7, and 14) remains a standard in many regions [231].
Pre-Exposure Prophylaxis (PrEP) Updates
PrEP is recommended for individuals at high risk of exposure, including veterinarians, laboratory workers, and travelers to endemic areas [56]D. The WHO now recommends an accelerated 2-dose intradermal regimen (administered on days 0 and 7) [237]D. This shift from the traditional 3-dose schedule is based on evidence that two doses provide sufficient priming for an anamnestic response upon later exposure [237]D. New serum-free, purified Vero cell rabies vaccines (PVRV-NG) are also being integrated into PrEP protocols due to their high immunogenicity and safety profiles [253].
Surveillance and Public Health Resources
Effective rabies control requires robust surveillance systems to identify potential exposures and monitor animal populations. In the United States, syndromic surveillance and "reverse 911" messaging have been utilized to identify persons exposed to rabid animal colonies [257]D[260]D.
- Bat Exposure Guidelines: Any direct contact with a bat, even if a bite is not recognized, requires a public health risk assessment. Failure to seek PEP after recognized bat encounters remains a primary cause of rabies deaths in the U.S. [184]D.
- Organ Transplantation: Guidelines now emphasize screening donors for rabies, especially if they exhibit unexplained neurological symptoms or have a history of animal bites (e.g., skunk or bat), to prevent human-to-human transmission [65]C.
- Diagnostic Tools: The Rapid Fluorescent Focus Inhibition Test (RFFIT) is the gold standard for quantifying rabies virus-neutralizing antibodies (RVNA) to assess vaccine efficacy [256]D. For antemortem diagnosis, metagenomic next-generation sequencing (mNGS) and PCR of saliva or skin biopsies are recommended, though sensitivity varies by timing [4]C[166]D.
Patient and Clinician Resources
- CDC Rabies Homepage: Provides updated maps of rabies variants (e.g., raccoon, skunk) and PEP calculators.
- WHO Rabies Fact Sheet: Offers global epidemiological data and "Zero by 30" progress reports [51]D.
- Traveler's Health: The Thai Travel Clinic and similar institutions provide specialized post-exposure consultations for international travelers [56]D.
| Regimen | Route | Schedule (Days) | Target Population |
|---|---|---|---|
| Essen Regimen | IM | 0, 3, 7, 14, (28*) | Standard IM protocol; 5th dose optional in some guidelines [231]. |
| WHO Shortened | ID | 0, 3, 7 | Preferred for cost-saving in endemic regions [234]D. |
| Zagreb Regimen | IM | 0 (2 doses), 7, 21 | 2-1-1 schedule for rapid induction [262]D. |
| PrEP (WHO) | ID/IM | 0, 7 | Accelerated priming for high-risk individuals [237]D. |
References
- [1]
Zoa JA, Njemguie Linjouom RM, Nyangono Ndongo M et al.. “Safety of RTS,S/AS01E vaccine for malaria in African children aged 5 to 17 months: A systematic review and meta-analysis of randomized controlled trials.” PLOS global public health (2025). PMID: 40522967 ↗
L1aSR_MA_RCTCited in: Definition, Synonyms, and Classification - [2]
Klyuchnikova E, Gladkikh A, Iunikhina O et al.. “Genomic and Clinical Analysis of a Fatal Human Lyssavirus irkut Case: Evidence for a Natural Focus in the Russian Far East.” Viruses (2025). PMID: 40573360 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors, Pathophysiology, Differential Diagnosis - [3]
Castillo Giraudo M, Orozco MM, Zabalza MJ et al.. “First Report of Paralytic Rabies in a Lowland Tapir (Tapirus terrestris) in Argentina.” Viruses (2025). PMID: 40285012 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors, Clinical Features and Variants, Differential Diagnosis - [4]
Wu J, Qi Y, Zhang W et al.. “Metagenomic next-generation sequencing for etiological diagnosis of an unexpected rabies case with unclear exposure history.” BMC infectious diseases (2025). PMID: 39994640 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors, Clinical Features and Variants, Guidelines and Resources - [5]
Jaswant G, Campbell K, Czupryna A et al.. “Molecular characterisation of human rabies in Tanzania and Kenya: a case series report and phylogenetic investigation.” Infectious diseases of poverty (2024). PMID: 39468631 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [6]
Rupprecht CE, Belsare AV, Cliquet F et al.. “The Challenge of Lyssavirus Infections in Domestic and Other Animals: A Mix of Virological Confusion, Consternation, Chagrin, and Curiosity.” Pathogens (Basel, Switzerland) (2025). PMID: 40559594 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors, Differential Diagnosis - [7]
Castelo-Branco DSCM, Nobre JA, Souza PRH et al.. “Role of Brazilian bats in the epidemiological cycle of potentially zoonotic pathogens.” Microbial pathogenesis (2023). PMID: 36804526 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [8]
Szieber D, Ábrahám Á, Bányai K et al.. “Detection and Phylogenetic Characterization of Canine Distemper Virus from a Red Fox in Hungary.” Viruses (2026). PMID: 41902260 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes - [9]
Robardet E, Smreczak M, Orłowska A et al.. “Rabies Reemergence, Central Europe, 2022-2024.” Emerging infectious diseases (2026). PMID: 41714846 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prevention and Screening - [10]
Rojas-Sereno ZE, Streicker DG, Yung V et al.. “Rabies, host population structure, and cross-species transmission to the migratory bat Tadarida brasiliensis in Chile.” PLoS neglected tropical diseases (2026). PMID: 41712612 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors - [11]
de Sousa LLF, Sanz Duro RL, de Oliveira Vaz R et al.. “Integrated molecular and metatranscriptomic evidence of Tacaribe virus and the brain virome profile of Molossus molossus bat sampled in Brazil.” Microbiology spectrum (2026). PMID: 41563065 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Pathophysiology - [12]
Queiroz LH, Campos ACA, Lopes MC et al.. “Evolutionary Diversity of Bat Rabies Virus in São Paulo State, Brazil.” Viruses (2025). PMID: 40872777 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [13]
Giménez AL, Zabalza MJ, Novaro LP et al.. “Diversity of Rabies Virus Variants in Insectivorous Bats (Chiroptera: Vespertilionidae and Molossidae): An Epidemiological Study in Central Argentine Patagonia.” Viruses (2025). PMID: 40573379 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors - [14]
Luo DS, Harazim M, Maufrais C et al.. “Broad geographical circulation of a novel vesiculovirus in bats in the Mediterranean region.” PLoS neglected tropical diseases (2025). PMID: 40504866 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [15]
Garcia-Oliveira GF, Frasson Biccas M, Jacob D et al.. “Human Herpesvirus 1 Associated with Epizootics in Belo Horizonte, Minas Gerais, Brazil.” Viruses (2025). PMID: 40431671 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [16]
Viljoen N, Sabeta C, Markotter W et al.. “Temporal and Spatial Analysis of Rabies Virus Lineages in South Africa.” Viruses (2025). PMID: 40143269 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors - [17]
Salazar R, Brunker K, Díaz EW et al.. “Genomic characterization of a dog-mediated rabies outbreak in El Pedregal, Arequipa, Peru.” PLoS neglected tropical diseases (2025). PMID: 40043048 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors - [18]
Caraballo DA, Vico ML, Piccirilli MG et al.. “Bat Rabies in the Americas: Is Myotis the Main Ancestral Spreader?” Viruses (2024). PMID: 39205276 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors - [19]
Wambugu EN, Kimita G, Kituyi SN et al.. “Geographic Distribution of Rabies Virus and Genomic Sequence Alignment of Wild and Vaccine Strains, Kenya.” Emerging infectious diseases (2024). PMID: 39043404 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors - [20]
Podgoreanu P, Petre A, Tănasă RI et al.. “Sequencing and Partial Molecular Characterization of BAB-TMP, the Babeș Strain of the Fixed Rabies Virus Adapted for Multiplication in Cell Lines.” Viruses (2023). PMID: 37766258 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [21]
Huaman C, Paskey AC, Clouse C et al.. “Genomic Surveillance of Rabies Virus in Georgian Canines.” Viruses (2023). PMID: 37766204 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [22]
Capin JBG, Sanque AJC, Eng MNJ et al.. “Emerging Genomic Trends on Rabies Virus in Davao Region, Philippines, 2018-2021.” Viruses (2023). PMID: 37632001 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [23]
de Sousa LLF, de Souza TL, Tibo LHS et al.. “Rabies virus variants from bats closely related to variants found in marmosets (Callithrix jacchus), a neglected source of human rabies infection in Brazil.” Journal of medical virology (2023). PMID: 37605969 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [24]
Dascalu MA, Picard-Meyer E, Robardet E et al.. “Whole genome sequencing and phylogenetic characterisation of rabies virus strains from Moldova and north-eastern Romania.” PLoS neglected tropical diseases (2023). PMID: 37410714 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [25]
Černe D, Hostnik P, Toplak I et al.. “Discovery of a novel bat lyssavirus in a Long-fingered bat (Myotis capaccinii) from Slovenia.” PLoS neglected tropical diseases (2023). PMID: 37384601 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [26]
Kunkel A, Veytsel G, Bonaparte S et al.. “Defining County-Level Terrestrial Rabies Freedom Using the US National Rabies Surveillance System: Surveillance Data Analysis.” JMIR public health and surveillance (2023). PMID: 37027194 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [27]
Mauhay JD, Saito N, Kimitsuki K et al.. “Molecular Analysis of Rabies Virus Using RNA Extracted from Used Lateral Flow Devices.” Journal of clinical microbiology (2023). PMID: 36840574 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [28]
Escobar LE, Velasco-Villa A, Satheshkumar PS et al.. “Revealing the complexity of vampire bat rabies "spillover transmission".” Infectious diseases of poverty (2023). PMID: 36782311 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [29]
Lungten L, Tenzin T, Thys S et al.. “An exploratory study on the perceptions of rabies and ill-health causations and health seeking behaviours of school children and local communities in southern Bhutan.” BMC public health (2023). PMID: 36750947 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [30]
Karagulov AI, Argimbayeva TU, Omarova ZD et al.. “The Prevalence of Viral Pathogens among Bats in Kazakhstan.” Viruses (2022). PMID: 36560747 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [31]
Regassa BT, Tosisa W, Eshetu D et al.. “Incidence, risk factors, and control of Rabies in Ethiopia: A systematic review and meta-analysis.” PLoS neglected tropical diseases (2025). PMID: 40106430 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [32]
Li G, Cao S, Xu B et al.. “Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10-60 years old.” Vaccine (2025). PMID: 40188565 ↗
L1bRCTCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Special Populations - [33]
Shams F, Jokar M, Djalali E et al.. “Incidence and prevalence of rabies virus infections in tested humans and animals in Asia: A systematic review and meta-analysis study.” One health (Amsterdam, Netherlands) (2025). PMID: 40535976 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [34]
Singkam N, Sapsirisavat V, Chanduan J et al.. “Delayed and incomplete rabies post-exposure prophylaxis among international travelers: A seven-year retrospective study at an emergency center in eastern Thailand.” Travel medicine and infectious disease (2025). PMID: 40602738 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [35]
Liu X, Zha Y, Wang Z et al.. “The pharmacokinetics and safety comparison of Zamerovimab and Mazorelvimab monoclonal antibodies vs. HRIG in category III rabies post-exposure prophylaxis: a stratified analysis by wound characteristics.” Biologicals : journal of the International Association of Biological Standardization (2025). PMID: 40812204 ↗
L1bRCTCited in: Epidemiology and Risk Factors, Management, Special Populations - [36]
Lv HK, Chen X, Xing B et al.. “A phase 3 clinical trial on the immunogenicity and safety of booster vaccination after Zagreb or Essen regimens.” Scientific reports (2025). PMID: 40016280 ↗
L1bRCTCited in: Epidemiology and Risk Factors - [37]
Peng PY, Xu L, Duan HY et al.. “One health perspectives on the epidemiological features and changing incidence of natural focus and vector-borne infectious diseases in China: An observational trend study.” One health (Amsterdam, Netherlands) (2026). PMID: 41993771 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Differential Diagnosis, Prognosis and Long-term Outcomes, Prevention and Screening - [38]
Gamble L, Fernandes KA, Tazawa K et al.. “Delivery of canine rabies vaccination programme in Kutupalong-Balukhali refugee camps, Cox's Bazar, Bangladesh.” PLoS neglected tropical diseases (2026). PMID: 41894416 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Management, Prevention and Screening - [39]
Chen S, Yang H, Deng Z et al.. “Analysis of Rabies Epidemiological Characteristics and Failed Post-Exposure Prophylaxis Cases - Hunan Province, China, 2019-2024.” China CDC weekly (2026). PMID: 41837254 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prevention and Screening - [40]
Xu H, Yan W, Ma Q. “Risk factors for adverse events following rabies vaccination: a multivariate analysis of real-world data.” Frontiers in public health (2026). PMID: 41717613 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Management, Prognosis and Long-term Outcomes, Prevention and Screening - [41]
Xie S, Shinnick J, Diaz EW et al.. “Socioeconomic disparities and dog rabies: a retrospective analysis of high-spatial-resolution surveillance data from a Latin American city.” Lancet regional health. Americas (2025). PMID: 41541761 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prevention and Screening - [42]
Chen L, Gao H, Zhang J et al.. “Impact of nonpharmaceutical interventions on infectious disease patterns in Yunnan Province across the COVID-19 pandemic phases.” BMC infectious diseases (2026). PMID: 41507827 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Guidelines and Resources - [43]
Zuo QY, Lv WW, Qin Y et al.. “Global burden and cross-country inequalities in rabies from 1990 to 2021: a systemic analysis of the global burden of disease study 2021.” BMC infectious diseases (2025). PMID: 41462130 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes, Prevention and Screening - [44]
Chen Q, Huang S, Shi L et al.. “Trends in the global and Chinese burden of rabies from 1990 to 2021 and forecasted to 2040: evidence from the Global Burden of Disease study 2021.” BMC infectious diseases (2025). PMID: 41449342 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes, Special Populations - [45]
Yathagiri N, Khan AM, Sharma R et al.. “Burden of dog bites and associated healthcare seeking behavior for rabies post-exposure prophylaxis in North and South Shahdara municipal zones of Delhi, India.” BMC public health (2025). PMID: 41354795 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Management, Special Populations - [46]
Tiwari HK, Mohanty P, Shirke RG et al.. “Two-leaves and many bites: Profiling dog-bites and adherence to rabies prophylaxis in tea-estate communities of Udalguri District, Assam, India.” PLoS neglected tropical diseases (2025). PMID: 41325464 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Management, Special Populations - [47]
Carroll SC, Castellanos ME, Neumayr A et al.. “What's the worst that could happen? The risk of illness, injury, and death related to international travel-the Australian experience.” Travel medicine and infectious disease (2025). PMID: 41213308 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [48]
He L, Tan EL. “From data to action: addressing geographic inequalities in rabies burden through targeted policies.” Frontiers in public health (2025). PMID: 41194997 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes - [49]
Chen X, Zhang J, Lyu S et al.. “Epidemiological Characteristics and Spatiotemporal Clustering Analysis of Human Rabies - China, 2005-2024.” China CDC weekly (2025). PMID: 41170169 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [50]
Wang Y, Xing X, Xiong Z et al.. “Overexpression of GitrL in Recombinant Rabies Virus rLBNSE-GitrL Enhances Innate Immunity by Activating Dendritic Cells and Innate Immune-Related Pathways and Genes.” Viruses (2025). PMID: 41157625 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes - [51]
Yang C, Dang M, Wu L et al.. “Disparities in Global Rabies Burden from GBD 2021: Children, older adults, and low-SDI countries at continued risk.” PLoS neglected tropical diseases (2025). PMID: 41105717 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Differential Diagnosis, Management, Prognosis and Long-term Outcomes, Special Populations, Guidelines and Resources - [52]
Hietanen H, Pfavayi LT, Mutapi F. “Unlocking the blueprint to eliminating neglected tropical diseases: A review of efforts in 50 countries that have eliminated at least 1 NTD.” PLoS neglected tropical diseases (2025). PMID: 40906712 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [53]
Ayachi A, Benabdallah R, Bouratbine A et al.. “Epidemiological Profiles of Human Rabies Cases in Tunisia Between 2000 and 2022.” Viruses (2025). PMID: 40733583 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Clinical Features and Variants, Special Populations - [54]
Zhang YF, Li SZ, Wang SW et al.. “Zoonotic diseases in China: epidemiological trends, incidence forecasting, and comparative analysis between real-world surveillance data and Global Burden of Disease 2021 estimates.” Infectious diseases of poverty (2025). PMID: 40616187 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Differential Diagnosis, Special Populations - [55]
Zha R, Lu J, Chen J et al.. “Exploring one health-based strategies for rabies elimination: Overview and future prospects.” PLoS neglected tropical diseases (2025). PMID: 40531916 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes - [56]
Charoenwisedsil R, Soravipukuntorn T, Panyatanakun K et al.. “Travel-related potential rabid animal post-exposure consultation at the Thai Travel Clinic, Hospital for Tropical Diseases, Bangkok, Thailand.” Travel medicine and infectious disease (2025). PMID: 40516802 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Guidelines and Resources - [57]
Yondo A, Enyetornye B, Velayudhan BT. “Insights into the occurrence of rabies viruses in multi-species animals based on diagnostic laboratory submissions.” Microbiology spectrum (2025). PMID: 40503830 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [58]
Chouhan CS, Raihan A, Mia MM et al.. “Demographic, temporal, and spatial analysis of human animal bite cases in Mymensingh District, Bangladesh.” PLoS neglected tropical diseases (2025). PMID: 40489552 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [59]
Niu J, Zhao Z, Zhang T et al.. “Development of an oral gut-targeted rabies virus-like particles (RVLPs) vaccine with mucosal immune adjuvant LTB via delivering of localized-release microparticles.” Emerging microbes & infections (2025). PMID: 40476513 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [60]
Ren Q, Chen N, Mu D et al.. “Characteristics, Post-exposure prophylaxis usage, and clinical features of Chinese human rabies cases, 2016-2020.” PLoS neglected tropical diseases (2025). PMID: 40465669 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [61]
Islam MM, Naeem A, Mshelbwala PP et al.. “Epidemiology, transmission dynamics, risk factors, and future directions of rabies in the Arabian Peninsula using one health approach: a review.” European journal of public health (2025). PMID: 39801328 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [62]
Fehlner-Gardiner C, Gongal G, Tenzin T et al.. “Rabies in Cats-An Emerging Public Health Issue.” Viruses (2024). PMID: 39459967 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [63]
Qiu Z, Liu X, Cao W et al.. “Role of Neurotropic Viruses in Brain Metastasis of Breast Cancer: Mechanisms and Therapeutic Implications.” Reviews in medical virology (2024). PMID: 39304923 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Prognosis and Long-term Outcomes - [64]
Law Wun M, Grandbesançon D, Cano P et al.. “Human rabies in Avignon, France, following exposure in Morocco, 2025.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41352756 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Management - [65]
Earnest R, Carter KK, Margrey SF et al.. “Human-to-Human Rabies Transmission via Solid Organ Transplantation from a Donor with Undiagnosed Rabies - United States, October 2024-February 2025.” MMWR. Morbidity and mortality weekly report (2025). PMID: 41343342 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Management, Guidelines and Resources - [66]
Liu P, Deng Z, Wang Y et al.. “Application of Probe-Capture metagenomics in rabies diagnosis.” Virology journal (2025). PMID: 41310694 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Diagnosis and Workup, Differential Diagnosis - [67]
Amaral Mali M, Machado FN, Moniz FP et al.. “The first confirmed human case of rabies, Timor-Leste, 2024.” Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (2024). PMID: 38699901 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [68]
Beniwal N, Lal B, Mithina S et al.. “Serological Assays to Measure Rabies Antibody Response in Equine Serum Samples.” Viruses (2026). PMID: 41600870 ↗
L5OTHERCited in: Etiology and Triggering Factors, Diagnosis and Workup - [69]
Klumb C, Ireland M, Miller B et al.. “Rabies Cluster Among Steers on a Dairy Farm - Minnesota, 2024.” MMWR. Morbidity and mortality weekly report (2025). PMID: 41379771 ↗
L5OTHERCited in: Etiology and Triggering Factors - [70]
Liu X, Ma J, Zhang Y et al.. “Virus-inspired nanocages potentiate glioblastoma sonochemotherapy via structure-function mimicry.” Acta biomaterialia (2025). PMID: 41106759 ↗
L5OTHERCited in: Etiology and Triggering Factors, Management - [71]
Van de Vuurst P, Rist C, Medina-Rodriguez T et al.. “Drivers of rabies virus spillover risk from vampire bats to livestock in Colombia.” PLoS neglected tropical diseases (2025). PMID: 41004516 ↗
L5OTHERCited in: Etiology and Triggering Factors, Prognosis and Long-term Outcomes - [72]
Tudhope E, Donnelly CM, Sethi A et al.. “The Replication Function of Rabies Virus P Protein Is Regulated by a Novel Phosphorylation Site in the N-Terminal N Protein-Binding Region.” Viruses (2025). PMID: 40872789 ↗
L5OTHERCited in: Etiology and Triggering Factors - [73]
English S, Fedosyuk S, Orliacq F et al.. “Rabies glycoprotein engineering for improved stability and expression.” Vaccine (2025). PMID: 40716142 ↗
L5OTHERCited in: Etiology and Triggering Factors - [74]
Wang S, Wang Z, Wang W et al.. “A VSV-based oral rabies vaccine was sentineled by Peyer's patches and induced a timely and durable immune response.” Molecular therapy : the journal of the American Society of Gene Therapy (2025). PMID: 40022445 ↗
L5OTHERCited in: Etiology and Triggering Factors, Pathophysiology - [75]
Yang Y, Hou M, Su G et al.. “Establishment of Echinococcus granulosus EgM123 Recombinant Gene Rabies Virus SRV9 and Identification of Its Biological Characteristics.” Viruses (2024). PMID: 39861819 ↗
L5OTHERCited in: Etiology and Triggering Factors - [76]
Lin X, Ghafuri A, Chen X et al.. “Projection-specific circuits of retrosplenial cortex with differential contributions to spatial cognition.” Molecular psychiatry (2025). PMID: 39511453 ↗
L5OTHERCited in: Etiology and Triggering Factors - [77]
Thangavelu K, Daniel HD, Kannangai R et al.. “Standardization and evaluation of an in-house ELISA for the detection of rabies antibody in a tertiary care centre in South India.” Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology (2024). PMID: 39499981 ↗
L5OTHERCited in: Etiology and Triggering Factors - [78]
Cai X, Zhou K, Alvarez-Cabrera AL et al.. “Structural Heterogeneity of the Rabies Virus Virion.” Viruses (2024). PMID: 39339924 ↗
L5OTHERCited in: Etiology and Triggering Factors - [79]
Ashraf HN, Uversky VN. “Intrinsic Disorder in the Host Proteins Entrapped in Rabies Virus Particles.” Viruses (2024). PMID: 38932209 ↗
L5OTHERCited in: Etiology and Triggering Factors - [80]
Mielcarska MB, Rouse BT. “Viruses and the Brain-A Relationship Prone to Trouble.” Viruses (2025). PMID: 40006958 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Differential Diagnosis - [81]
Chu H, Sun Y, Huang C et al.. “Polydopamine Modified with Brain Targeting Peptide Rabies Virus Glycoprotein for Treatment of Alzheimer's Disease by Inhibiting Oxidative Stress and Inflammatory Response.” International journal of nanomedicine (2026). PMID: 41884282 ↗
L5OTHERCited in: Pathophysiology - [82]
Bertoune MAR, Kolbe C, Werner AC et al.. “Combined Glycoprotein Mutations in Rabies Virus Promote Astrocyte Tropism and Protective CNS Immunity in Mice.” Viruses (2026). PMID: 41754524 ↗
L5OTHERCited in: Pathophysiology, Differential Diagnosis, Prognosis and Long-term Outcomes - [83]
Quansah Amissah R, Hanafy MK, Kayir H et al.. “An Open-Source Restraint System for Magnetic Resonance Imaging in Awake Rats.” eNeuro (2026). PMID: 41748433 ↗
L5OTHERCited in: Pathophysiology, Diagnosis and Workup, Management - [84]
Xu Y, Zhao JY, Xu XY et al.. “Engineered Biomimetic Nanorobots Orchestrate Targeted Nose-to-Brain Delivery to Resolve Neuron-Glia Entanglement against Parkinson's Disease.” Small (Weinheim an der Bergstrasse, Germany) (2026). PMID: 41607240 ↗
L5OTHERCited in: Pathophysiology, Management - [85]
Tan K, Wang YQ, Yang RR et al.. “Development and application of a barcoded rabies viral tracing method for mapping brain-wide inputs to single neurons.” Cell reports methods (2025). PMID: 41338190 ↗
L5OTHERCited in: Pathophysiology, Diagnosis and Workup - [86]
Tan K, Shen ZX, Wang YQ et al.. “One-step approach producing barcoded rabies virus with optimized diversity.” Cell reports methods (2025). PMID: 41338187 ↗
L5OTHERCited in: Pathophysiology - [87]
Bao H, Hu Z, Lee SH et al.. “Aberrantly integrated adult-born immature neurons disrupt brain-wide networks during spatial memory processing.” Molecular psychiatry (2026). PMID: 41275018 ↗
L5OTHERCited in: Pathophysiology, Diagnosis and Workup - [88]
Zhao Y, Xie WL, Liu Y et al.. “Extracellular vesicle-based bumetanide delivery alleviates depression-like behaviors of male mice by restoring chloride homeostasis.” Molecular therapy : the journal of the American Society of Gene Therapy (2026). PMID: 41137395 ↗
L5OTHERCited in: Pathophysiology - [89]
Klug JR, Yan X, Hoffman H et al.. “Asymmetric cortical projections to striatal direct and indirect pathways distinctly control actions.” eLife (2025). PMID: 41118233 ↗
L5OTHERCited in: Pathophysiology - [90]
Henriques C, Albuquerque P, Rufino-Ramos D et al.. “Extracellular vesicles-associated AAVs for the treatment of Machado-Joseph disease.” Molecular therapy : the journal of the American Society of Gene Therapy (2026). PMID: 41077785 ↗
L5OTHERCited in: Pathophysiology - [91]
Rashid M, Thomas S, Isaac J et al.. “A ventral hippocampal-lateral septum pathway regulates social novelty preference.” eLife (2025). PMID: 40464663 ↗
L5OTHERCited in: Pathophysiology, Diagnosis and Workup - [92]
Ma MF, Hu J, Hao YX et al.. “Whole Brain Monosynaptic Input of Distinct Neurons in the Globus Pallidus Externa.” CNS neuroscience & therapeutics (2025). PMID: 40464272 ↗
L5OTHERCited in: Pathophysiology - [93]
Sun C, Sha S, Shan Y et al.. “Intranasal Delivery of BACE1 siRNA and Berberine via Engineered Stem Cell Exosomes for the Treatment of Alzheimer's Disease.” International journal of nanomedicine (2025). PMID: 40351705 ↗
L5OTHERCited in: Pathophysiology - [94]
Yang H, Yang M, Xu T. “Whole-brain input architecture of primary and secondary somatosensory cortices in mice.” Molecular pain (2025). PMID: 40346961 ↗
L5OTHERCited in: Pathophysiology - [95]
Summers BS, Blizzard CA, Ricci RR et al.. “Demyelination Produces a Shift in the Population of Cortical Neurons That Synapse with Callosal Oligodendrocyte Progenitor Cells.” eNeuro (2025). PMID: 40345851 ↗
L5OTHERCited in: Pathophysiology - [96]
Qin Q, Li M, Fan L et al.. “RVG engineered extracellular vesicles-transmitted miR-137 improves autism by modulating glucose metabolism and neuroinflammation.” Molecular psychiatry (2025). PMID: 40175518 ↗
L5OTHERCited in: Pathophysiology - [97]
Shi X, Zhang L, Wu S et al.. “A simple polydopamine-based platform for engineering extracellular vesicles with brain-targeting peptide and imaging probes to improve stroke outcome.” Journal of extracellular vesicles (2025). PMID: 39783851 ↗
L5OTHERCited in: Pathophysiology - [98]
Berg LJ, Lee CK, Matsumura H et al.. “Human neural stem cells directly programmed from peripheral blood show functional integration into the adult mouse brain.” Stem cell research & therapy (2024). PMID: 39707492 ↗
L5OTHERCited in: Pathophysiology - [99]
Rebollada-Merino A, Pumarola M, Ferrer I. “Altered endoplasmic reticulum stress response in non-infectious neuronal cytoplasmic inclusions in the brain of an aged dog.” Veterinary research communications (2025). PMID: 41114909 ↗
L4CASE_REPORTCited in: Pathophysiology - [100]
de Mello Zanim M, Rodriguez MC, Martins FDC et al.. “Immunohistochemical and molecular confirmation of West Nile Virus associated polioencephalomyelitis in a mule from Southern Brazil.” Microbial pathogenesis (2025). PMID: 40930439 ↗
L4CASE_REPORTCited in: Pathophysiology - [101]
Nujum ZT, Valamparampil MJ, Rajagopal MR et al.. “Efficacy of 2% lignocaine medicated pad for pain alleviation during rabies immunoglobulin administration: A randomized controlled trial.” Indian journal of public health (2021). PMID: 34975078 ↗
L1bRCTCited in: History and Physical Examination - [102]
Kennedy SA, Stoll LE, Lauder AS. “Human and other mammalian bite injuries of the hand: evaluation and management.” The Journal of the American Academy of Orthopaedic Surgeons (2015). PMID: 25538130 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [103]
Downs CJ, Schoenle LA, Han BA et al.. “Scaling of Host Competence.” Trends in parasitology (2019). PMID: 30709569 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [104]
Marosi A, Dufkova L, Forró B et al.. “Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin.” Vaccine (2019). PMID: 29805091 ↗
L5OTHERCited in: History and Physical Examination - [105]
Nakagawa K, Ito N, Masatani T et al.. “Generation of a live rabies vaccine strain attenuated by multiple mutations and evaluation of its safety and efficacy.” Vaccine (2012). PMID: 22464967 ↗
L5OTHERCited in: History and Physical Examination - [106]
Healy DM, Brookes SM, Banyard AC et al.. “Pathobiology of rabies virus and the European bat lyssaviruses in experimentally infected mice.” Virus research (2013). PMID: 23274107 ↗
L5OTHERCited in: History and Physical Examination - [107]
Xiao XX, Zhang Y, Liu JX et al.. “Immunoenhancement with flagellin as an adjuvant to whole-killed rabies vaccine in mice.” Archives of virology (2016). PMID: 26650039 ↗
L5OTHERCited in: History and Physical Examination - [108]
Gunn-Moore DA, Reed N. “CNS disease in the cat: current knowledge of infectious causes.” Journal of feline medicine and surgery (2011). PMID: 22063207 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [109]
Takayama-Ito M, Lim CK, Nakamichi K et al.. “Reduction of animal suffering in rabies vaccine potency testing by introduction of humane endpoints.” Biologicals : journal of the International Association of Biological Standardization (2017). PMID: 28040390 ↗
L5OTHERCited in: History and Physical Examination - [110]
Bao B, Fu K, Zheng X et al.. “Novel method for restoration of anorectal function following spinal cord injury via nerve transfer in rats.” The journal of spinal cord medicine (2020). PMID: 29509106 ↗
L5OTHERCited in: History and Physical Examination - [111]
Berndtsson LT, Nyman AK, Rivera E et al.. “Factors associated with the success of rabies vaccination of dogs in Sweden.” Acta veterinaria Scandinavica (2011). PMID: 21439029 ↗
L5OTHERCited in: History and Physical Examination - [112]
Dunbar MR, MacCarthy KA. “Use of infrared thermography to detect signs of rabies infection in raccoons (Procyon lotor).” Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians (2006). PMID: 17315437 ↗
L5OTHERCited in: History and Physical Examination - [113]
Lacy M, Phasuk N, Scholand SJ. “Human Rabies Treatment-From Palliation to Promise.” Viruses (2024). PMID: 38275970 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants - [114]
Scott TP, Nel LH. “Lyssaviruses and the Fatal Encephalitic Disease Rabies.” Frontiers in immunology (2021). PMID: 34925368 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants - [115]
Ugolini G, Hemachudha T. “Rabies: changing prophylaxis and new insights in pathophysiology.” Current opinion in infectious diseases (2018). PMID: 29293476 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants - [116]
Li R, Jin C, Zhang Z et al.. “Targeted next-generation sequencing confirms rabies in a patient with unknown exposure: a case report.” Frontiers in medicine (2026). PMID: 41994421 ↗
L4CASE_REPORTCited in: Clinical Features and Variants - [117]
Deschamps N, Mayence C, Parize P et al.. “Paralytic rabies outbreak mimicking guillain-Barré syndrome in French Amazonia.” PLoS neglected tropical diseases (2026). PMID: 41911281 ↗
L4CASE_REPORTCited in: Clinical Features and Variants, Diagnosis and Workup, Differential Diagnosis - [118]
Lin B, Zhong D, Qin L et al.. “Application of metagenomics sequencing to diagnose paralytic rabies with stroke-like onset: a case report.” Frontiers in medicine (2025). PMID: 40933579 ↗
L4CASE_REPORTCited in: Clinical Features and Variants - [119]
Dorji T, Lamichaney J, Gyaltshen C et al.. “Human rabies encephalomyelitis in the background of rabies outbreak in animals in Gelephu, Bhutan, 2023: a case report.” Infectious diseases of poverty (2023). PMID: 37845744 ↗
L4CASE_REPORTCited in: Clinical Features and Variants - [120]
Wang PH, Xing L. “The roles of rabies virus structural proteins in immune evasion and implications for vaccine development.” Canadian journal of microbiology (2024). PMID: 39297428 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants - [121]
Harada M, Matsuu A, Kaku Y et al.. “Single Amino Acid Substitution in the Matrix Protein of Rabies Virus Is Associated with Neurovirulence in Mice.” Viruses (2024). PMID: 38793581 ↗
L5OTHERCited in: Clinical Features and Variants - [122]
Guzman FD, Iwamoto Y, Saito N et al.. “Clinical, epidemiological, and spatial features of human rabies cases in Metro Manila, the Philippines from 2006 to 2015.” PLoS neglected tropical diseases (2022). PMID: 35852994 ↗
L5OTHERCited in: Clinical Features and Variants - [123]
Delpietro HA, Russo RG, Rupprecht CE et al.. “Towards Development of an Anti-Vampire Bat Vaccine for Rabies Management: Inoculation of Vampire Bat Saliva Induces Immune-Mediated Resistance.” Viruses (2021). PMID: 33804644 ↗
L5OTHERCited in: Clinical Features and Variants - [124]
Bhat MD, Priyadarshini P, Prasad C et al.. “Neuroimaging Findings in Rabies Encephalitis.” Journal of neuroimaging : official journal of the American Society of Neuroimaging (2021). PMID: 33534937 ↗
L5OTHERCited in: Clinical Features and Variants - [125]
Reed M, Stuchlik O, Carson WC et al.. “Novel mass spectrometry based detection and identification of variants of rabies virus nucleoprotein in infected brain tissues.” PLoS neglected tropical diseases (2018). PMID: 30550539 ↗
L5OTHERCited in: Clinical Features and Variants - [126]
Wong KA, Rusli AB, Bobby GA et al.. “First detection of rabies virus in encephalitic goats (Capra hircus) from Sarawak, Malaysian Borneo: a case study report.” BMC veterinary research (2025). PMID: 41194146 ↗
L4CASE_REPORTCited in: Clinical Features and Variants - [127]
Torres-Pérez ME, Reyes-Cortés IB, Romero-Ramos EM et al.. “Rabies, the cause of fatal encephalitis.” Salud publica de Mexico (2023). PMID: 36750077 ↗
L4CASE_REPORTCited in: Clinical Features and Variants - [128]
Franco-Molina MA, Santana-Krímskaya SE, Cortés-García B et al.. “Fatal Case of Rabies in a Captive White-Tailed Deer: A Case Report from Chiapas, Mexico.” Tropical medicine and infectious disease (2021). PMID: 34287376 ↗
L4CASE_REPORTCited in: Clinical Features and Variants - [129]
Bharti OK, Tekta D, Shandil A et al.. “Failure of postexposure prophylaxis in a girl child attacked by rabid dog severing her facial nerve causing possible direct entry of rabies virus into the facial nerve.” Human vaccines & immunotherapeutics (2019). PMID: 31035833 ↗
L4CASE_REPORTCited in: Clinical Features and Variants - [130]
Moreira IL, de Sousa DER, Ferreira-Junior JA et al.. “Paralytic rabies in a goat.” BMC veterinary research (2018). PMID: 30419906 ↗
L4CASE_REPORTCited in: Clinical Features and Variants - [131]
Bharti OK, Sharma V. “Failure of Postexposure Prophylaxis in a Patient Given Rabies Vaccine Intramuscularly in the Gluteus Muscle, Himachal Pradesh, India.” Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine (2018). PMID: 29657377 ↗
L4CASE_REPORTCited in: Clinical Features and Variants - [132]
Cao L, Wang X, Zhou Y et al.. “Diagnosis of Paralytic Rabies by Metagenomics Next-Generation Sequencing: A Case Report and Review of the Literature.” Veterinary medicine and science (2026). PMID: 41556741 ↗
L4CASE_REPORTCited in: Clinical Features and Variants - [133]
Liu X, Li J, Zha Y et al.. “The efficacy and safety of SYN023 (Zamerovimab and Mazorelvimab injection), the recombinant humanized anti-rabies virus monoclonal antibody mixture, combined with rabies vaccine in a WHO category III rabies post-exposure population: A randomized, double-blind, positive control, phase III clinical trial.” Vaccine (2025). PMID: 40479926 ↗
L1bRCTCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes, Special Populations - [134]
Liang Z, Chen X, Xing B et al.. “Safety, immunogenicity and immune-persistence of a lyophilized human rabies vaccine (Vero cells) under Zagreb and Essen regimens: a randomized, open-label, controlled phase III clinical trial in healthy participants aged 10-60 years in China.” Frontiers in immunology (2024). PMID: 39575262 ↗
L1bRCTCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes, Special Populations - [135]
Hagouch A, Rouillon N, Kabbadj A et al.. “Mirrored Self-Misidentification Syndrome: A Systematic Review of Cases.” Journal of geriatric psychiatry and neurology (2025). PMID: 40294306 ↗
L2aSR_OBSCited in: Diagnosis and Workup - [136]
Li J, Wu Z, Wu X et al.. “Safety and immunogenicity of freeze-dried human rabies vaccines: A phase 3 clinical trial of Zagreb and Essen regimes.” Human vaccines & immunotherapeutics (2024). PMID: 39535124 ↗
L1bRCTCited in: Diagnosis and Workup, Special Populations - [137]
Embregts CWE, Salahuddin N, Gohar MA et al.. “Detection of rabies virus RNA in dog-bite wounds in a rabies-endemic area: evidence from an observational cohort study.” EBioMedicine (2026). PMID: 41966876 ↗
L2bCOHORTCited in: Diagnosis and Workup - [138]
McNulty MA, Agosto ER. “Infection Risk From Humans and Animals in the Anatomy Laboratory: A Scoping Review.” Clinical anatomy (New York, N.Y.) (2026). PMID: 41334985 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [139]
Patel C, Wang X, Giles M et al.. “The role of serological testing for vaccination with a focus on immunocompromised patients: a synthesis of current evidence.” Vaccine (2025). PMID: 40857937 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Management, Special Populations - [140]
Burnett EJ, Mcpherson RJ, Aquin JP et al.. “Long-term serological response and boostability of intradermal rabies immunization: A retrospective chart review.” Canadian journal of public health = Revue canadienne de sante publique (2025). PMID: 39592563 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [141]
Lodha L, Ananda AM, Mani RS. “Advancing Rabies Diagnosis: Time for a New "Gold Standard"?” Molecular diagnosis & therapy (2025). PMID: 39560914 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Guidelines and Resources - [142]
De Pijper CA, van Thiel PPAM, van de Beek D et al.. “Rabies in humans: A treatment approach.” Travel medicine and infectious disease (2025). PMID: 39922333 ↗
L4CASE_REPORTCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes - [143]
McElhinney LM, Chaves LB, Petit C et al.. “Workshop report: Improving standardisation of rabies serology methods and procedures.” Vaccine (2026). PMID: 41747337 ↗
L5OTHERCited in: Diagnosis and Workup - [144]
Harris J, Alexander K, Hutchinson P et al.. “Evaluation of Risk Factors for Failed Seroconversion in the Management of Potential Lyssavirus Exposures.” Open forum infectious diseases (2026). PMID: 41696414 ↗
L5OTHERCited in: Diagnosis and Workup - [145]
Ashwath Narayana DH, Poornima MK, Chiranthan CM et al.. “Effectiveness of rabies immunoglobulins and monoclonal antibodies infiltrated into animal bite wounds after dilution: Real-world evidence from an anti-rabies clinic in India.” Vaccine (2026). PMID: 41576704 ↗
L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes, Special Populations - [146]
Wu X, Wang L, He C et al.. “Establishment of rapid saturation mutagenesis and screening methods for improving the neutralizing activity of monoclonal antibodies.” Frontiers in immunology (2025). PMID: 41394819 ↗
L5OTHERCited in: Diagnosis and Workup - [147]
Tibavija SS, Almario MP, Jaramillo V et al.. “Validation and evaluation of the rapid fluorescent focus inhibition test (RFFIT) for the quantification of neutralizing antibodies as an indirect measure of rabies vaccine relative potency: An alternative to the NIH test.” Vaccine (2025). PMID: 40934733 ↗
L5OTHERCited in: Diagnosis and Workup - [148]
Drzewnioková P, Brian I, Mancin M et al.. “Validation and multi-site deployment of a lyophilized qRT-PCR reagent for the molecular diagnosis of avian influenza and rabies in Sub-Saharan African regions.” Journal of clinical microbiology (2025). PMID: 40590553 ↗
L5OTHERCited in: Diagnosis and Workup - [149]
Tchos KF, Ridzon R, Haidara MC et al.. “Investigating immune amnesia after measles virus infection in two West African countries: A study protocol.” PloS one (2025). PMID: 40569945 ↗
L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Special Populations - [150]
Li J, Yang Y, Jia K et al.. “Exposed nucleoprotein inside rabies virus particle as an ideal target for real-time quantitative evaluation of rabies virus particle integrity in vaccine quality control.” PLoS neglected tropical diseases (2025). PMID: 40445993 ↗
L5OTHERCited in: Diagnosis and Workup - [151]
Xiao Y, Wu M, Xu W et al.. “Development and validation of a blocking ELISA for measurement of rabies virus neutralizing antibody.” Journal of clinical microbiology (2025). PMID: 40366189 ↗
L5OTHERCited in: Diagnosis and Workup - [152]
Song Y, Zeng J, Han Y et al.. “Green-to-red spectral labeling: A novel polysynaptic retrograde tracing strategy in the marker footprint mouse model.” Animal models and experimental medicine (2025). PMID: 40275744 ↗
L5OTHERCited in: Diagnosis and Workup - [153]
Asres GD, Gessesse YK, Salew D et al.. “Traditional medicine use among rabies exposed individuals in Ethiopia: A systematic review and meta-analysis.” PLoS neglected tropical diseases (2025). PMID: 40644528 ↗
L2aSR_OBSCited in: Differential Diagnosis - [154]
Niyati R, Rezahosseini O, Ekenberg C et al.. “Immunogenicity and Safety of Pneumococcal Vaccines Co-Administered with Common Travel Vaccines in Adults: A Systematic Review.” Vaccines (2025). PMID: 40573974 ↗
L2aSR_OBSCited in: Differential Diagnosis - [155]
Maley G, Patel N, Crihălmeanu T et al.. “Management of Wild, Noncanine Mammalian Attacks Complicated by Bacterial Infection: A Case Report and Systematic Literature Review.” The Journal of emergency medicine (2025). PMID: 40533371 ↗
L2aSR_OBSCited in: Differential Diagnosis, Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [156]
Jelinek T, Schunk M, Reisinger EC et al.. “Long-term persistence and boostability of immune responses following different rabies pre-exposure prophylaxis priming schedules of a purified chick embryo cell rabies vaccine administered alone or concomitantly with a Japanese encephalitis vaccine.” PLoS neglected tropical diseases (2025). PMID: 40424340 ↗
L2bTRIAL_NONRANDOMCited in: Differential Diagnosis - [157]
Sarkar S, Biligiri KK, Vats N et al.. “Participation of host cell proteins in inclusion bodies of non-segmented RNA virus infected cells: a molecular insight.” Virology journal (2025). PMID: 40826091 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [158]
Stanic T, Koiso S, Fields NF et al.. “Economic value of pre-travel health interventions for communicable diseases in international travellers.” Journal of travel medicine (2025). PMID: 40581744 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [159]
Hooi YT, Fu TL, Tan SH et al.. “Neuroinvasion via Peripheral Nerves in Epidemic Viral Encephalitis Caused by Enterovirus, Orthoflavivirus and SARS-Coronavirus.” Neuropathology and applied neurobiology (2025). PMID: 39989030 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [160]
Mou L, Wang H, Li J et al.. “Rabies presenting as acute psychiatric behavioral abnormality with delayed onset after dog bite: A fatal case report.” Diagnostic microbiology and infectious disease (2025). PMID: 40408828 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [161]
Hurmuzache M, Gradinaru MA, Bărbuceanu F et al.. “Death in the EU/EEA from autochthonous human rabies, Romania, July 2025: a call for action.” Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (2025). PMID: 41170571 ↗
L4CASE_REPORTCited in: Differential Diagnosis, Management - [162]
Wang Q, Liao L, Sun D et al.. “Descriptive epidemiology of animal-induced injuries in Sandun Town, Hangzhou, China.” Frontiers in public health (2025). PMID: 41584198 ↗
L5OTHERCited in: Differential Diagnosis, Special Populations, Prevention and Screening - [163]
Stachura K, Davis R, Carritt K et al.. “A Novel, Safe, Non-Adjuvanted Alphavirus RNA Particle Vaccine Expressing the Rabies Virus Glycoprotein Induces a Three-Year Duration of Immunity in Dogs and Cats After a Single Vaccine Dose.” Vaccines (2025). PMID: 41441643 ↗
L5OTHERCited in: Differential Diagnosis, Prevention and Screening - [164]
Tiwari S, Roy I, Daptardar M et al.. “Transforming One Health in India: National Multisectoral Mixed Method Study on Prioritization of Zoonotic Diseases.” JMIR public health and surveillance (2025). PMID: 41429420 ↗
L5OTHERCited in: Differential Diagnosis - [165]
Lodha L, Gupta S, Ashwini MA et al.. “Rabies Despite Post-Exposure Prophylaxis in High-Burden Settings: Vaccine Failure or Gaps in Healthcare Delivery?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 41350240 ↗
L5OTHERCited in: Differential Diagnosis - [166]
Swedberg C, Cash-Goldwasser S, Ross Y et al.. “Maximizing Human Rabies Case Detection: Understanding the Diagnostic Sensitivity of Antemortem Testing from 35 Years of U.S. Data.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 41344318 ↗
L5OTHERCited in: Differential Diagnosis, Guidelines and Resources - [167]
Reifler KA, Sharma SS, Bergren NA et al.. “Ready for takeoff? exploring United States health care providers' pretravel consultation priorities, gaps, barriers, and opportunities.” Travel medicine and infectious disease (2025). PMID: 41038602 ↗
L5OTHERCited in: Differential Diagnosis - [168]
Harisha KR, Kailaje V, Kondreddi RR et al.. “Homoharringtonine Inhibits CVS-11 and Clinical Isolates of Rabies Virus In Vitro: Identified via High-Throughput Screening of an FDA-Approved Drug Library.” Viruses (2025). PMID: 40733562 ↗
L5OTHERCited in: Differential Diagnosis - [169]
Huang M, Li J, Li J et al.. “Aglycone Polyether Ionophores Affecting Actin Filaments as Broad-Spectrum Antiviral Agents.” ACS pharmacology & translational science (2025). PMID: 40672661 ↗
L5OTHERCited in: Differential Diagnosis - [170]
Jin K, Huang P, Li B et al.. “A Single-Copy Sensitive and Field-Deployable One-Pot RT-RPA CRISPR/Cas12a Assay for the Specific Visual Detection of the Nipah Virus.” Transboundary and emerging diseases (2024). PMID: 40303110 ↗
L5OTHERCited in: Differential Diagnosis - [171]
Dymock M, Marsh JA, Murray K et al.. “What is the quality of evidence informing vaccine clinical practice recommendations in Australia?” Vaccine (2025). PMID: 40215704 ↗
L5OTHERCited in: Differential Diagnosis - [172]
Tiwary R, Shekhar P, Kumar P et al.. “Rabies in a Captive Asian Elephant (Elephas maximus) in Bihar, India: First Confirmed Case With Ante- and Post-Mortem Diagnostics.” Zoonoses and public health (2026). PMID: 41639971 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [173]
Osei-Tutu L, Kariuki SK, Lee CK et al.. “Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial.” The Lancet. Global health (2025). PMID: 40975080 ↗
L1bRCTCited in: Management - [174]
Kulkarni PS, Potey AV, Kapse D et al.. “Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial.” Lancet (London, England) (2025). PMID: 40783290 ↗
L1bRCTCited in: Management, Special Populations - [175]
Ashwini MA, Gupta S, Lodha L et al.. “Immunogenicity of the abbreviated one-week intradermal rabies pre-exposure prophylaxis and its boostability in health-care workers: A retrospective observational cohort study.” Vaccine (2025). PMID: 41016232 ↗
L2bCOHORTCited in: Management - [176]
Yale G, Freuling C, Gibson A et al.. “Human safety of SPBN GASGAS for oral rabies vaccination of dogs.” PLoS neglected tropical diseases (2026). PMID: 41525297 ↗
L5REVIEW_NARRATIVECited in: Management, Prevention and Screening - [177]
Barger A, Margrey SF, Siu AW et al.. “Imported Human Rabies - Kentucky and Ohio, 2024.” MMWR. Morbidity and mortality weekly report (2026). PMID: 41538367 ↗
L4CASE_REPORTCited in: Management - [178]
Sagaser J, Jones J, Baird M et al.. “Needle replacement before subcutaneous vaccination in dogs: a randomized clinical trial finds no clinical benefit.” Journal of the American Veterinary Medical Association (2026). PMID: 41442842 ↗
L1bRCTCited in: Management, Prevention and Screening - [179]
Das M, Yustyniuk V, Perez AM et al.. “Global Perspectives on Rabies Control and Elimination: A Scoping Review of Dog Owners' Knowledge, Attitudes, and Practices.” Pathogens (Basel, Switzerland) (2025). PMID: 40872238 ↗
L5REVIEW_NARRATIVECited in: Management - [180]
Shwiff S, Swanson G, Shwiff S et al.. “Cost effectiveness of the Texas wildlife rabies Border Maintenance Zone.” PLoS neglected tropical diseases (2026). PMID: 41920858 ↗
L5OTHERCited in: Management, Prevention and Screening - [181]
Lu Y, Xie H, Wu K et al.. “A portable bilayer microneedle patch for rapid and patient-friendly administration of rabies immunoglobulin and enhanced wound healing.” Journal of materials chemistry. B (2026). PMID: 41574942 ↗
L5OTHERCited in: Management, Prevention and Screening - [182]
Changalucha J, Ferguson E, Luka MM et al.. “Comparative effectiveness and cost-effectiveness of policies for provisioning rabies post-exposure vaccines.” Vaccine (2026). PMID: 41564610 ↗
L5OTHERCited in: Management - [183]
Zhu T, Chang X, Wu X et al.. “Animal rabies prevention and control in Shanghai, China: policies and practices, 2011-2025.” Frontiers in public health (2025). PMID: 41561872 ↗
L5OTHERCited in: Management, Prevention and Screening - [184]
Ireland M, Fritz CL, Holzbauer S et al.. “Human Rabies Deaths - Minnesota and California, 2024.” MMWR. Morbidity and mortality weekly report (2026). PMID: 41538369 ↗
L5OTHERCited in: Management, Special Populations, Guidelines and Resources - [185]
Banza Kongolo H, Peng Y, Chan M et al.. “Drivers of rabies post-exposure prophylaxis noncompletion in Cambodia, 2019 to 2022.” PLoS neglected tropical diseases (2025). PMID: 41411369 ↗
L5OTHERCited in: Management, Special Populations, Prevention and Screening - [186]
Smets L, Jaiswar SK, Stienen V et al.. “Towards "Zero by 30", the Kenyan case: a systematic exploration of barriers to rabies policy implementation through systems thinking.” Health research policy and systems (2025). PMID: 41372783 ↗
L5OTHERCited in: Management - [187]
Weber L, O'Brien BCV, Weltzin MM. “Development of a novel alpha7-nicotinic acetylcholine receptor-selective cell-penetrating peptide for intracellular cargo transport.” Drug delivery (2025). PMID: 41319151 ↗
L5OTHERCited in: Management - [188]
Shwiff SA, Acheson ES, Altringer L et al.. “Benefit-cost analysis of raccoon rabies control in Ontario, Canada.” PLoS neglected tropical diseases (2025). PMID: 41296778 ↗
L5OTHERCited in: Management - [189]
de Feij M, Luppino FS, Visser LG et al.. “Delays in rabies post-exposure prophylaxis abroad.” Journal of travel medicine (2025). PMID: 41123543 ↗
L5OTHERCited in: Management - [190]
Kappagoda S, Ioannidis JP. “Neglected tropical diseases: survey and geometry of randomised evidence.” BMJ (Clinical research ed.) (2012). PMID: 23089149 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [191]
Shingde R, Habachou LI, Calisa V et al.. “Unexpected donor-derived infectious transmissions by kidney transplantation: A systematic review.” Transplant infectious disease : an official journal of the Transplantation Society (2018). PMID: 29508947 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [192]
Silverberg B, Moyers A, Wainblat BI et al.. “A Stitch in Time: Operative and Nonoperative Laceration Repair Techniques.” Primary care (2022). PMID: 35125156 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [193]
Greene SE, Fritz SA. “Infectious Complications of Bite Injuries.” Infectious disease clinics of North America (2021). PMID: 33494873 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [194]
Dhillon J, Hoopes J, Epp T. “Scoping decades of dog evidence: a scoping review of dog bite-related sequelae.” Canadian journal of public health = Revue canadienne de sante publique (2019). PMID: 30378009 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [195]
Carod-Artal FJ. “Infectious diseases causing autonomic dysfunction.” Clinical autonomic research : official journal of the Clinical Autonomic Research Society (2018). PMID: 28730326 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [196]
Berkowitz AL, Raibagkar P, Pritt BS et al.. “Neurologic manifestations of the neglected tropical diseases.” Journal of the neurological sciences (2015). PMID: 25623803 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [197]
Murthy S, Keystone J, Kissoon N. “Infections of the developing world.” Critical care clinics (2013). PMID: 23830650 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [198]
Esposito S, Picciolli I, Semino M et al.. “Dog and cat bite-associated infections in children.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2013). PMID: 23404346 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [199]
Eckerle I, Rosenberger KD, Zwahlen M et al.. “Serologic vaccination response after solid organ transplantation: a systematic review.” PloS one (2013). PMID: 23451126 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [200]
De Benedictis P, Perboni G, Gentili C et al.. “Fatal case of human rabies imported to Italy from India highlights the importance of adequate post-exposure prophylaxis, October 2011.” Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (2012). PMID: 22607965 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [201]
Shah I. “Acute demyelinating encephalomyelitis due to neural antirabies vaccine.” Journal of travel medicine (2008). PMID: 18217872 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [202]
Septelici D, Carbone G, Cipri A et al.. “Management Strategies for Common Animal Bites in Pediatrics: A Narrative Review on the Latest Progress.” Microorganisms (2024). PMID: 38792754 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [203]
Warrell M, Warrell DA, Tarantola A. “The Imperative of Palliation in the Management of Rabies Encephalomyelitis.” Tropical medicine and infectious disease (2017). PMID: 30270909 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [204]
Agrawal A, Kumar P, Singhal R et al.. “Animal Bite Injuries in Children: Review of Literature and Case Series.” International journal of clinical pediatric dentistry (2017). PMID: 28377659 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [205]
Piyaphanee W, Stoney RJ, Asgeirsson H et al.. “Healthcare seeking during travel: an analysis by the GeoSentinel surveillance network of travel medicine providers.” Journal of travel medicine (2023). PMID: 36637429 ↗
L5OTHERCited in: Supportive Care and Complication Management - [206]
Williams BM, Purcell L, Kayange L et al.. “Characteristic and outcomes of human and animal bites in Malawi.” Injury (2021). PMID: 33785190 ↗
L5OTHERCited in: Supportive Care and Complication Management - [207]
Nguyen HTT, Tran CH, Dang AD et al.. “Rabies Vaccine Hesitancy and Deaths Among Pregnant and Breastfeeding Women - Vietnam, 2015-2016.” MMWR. Morbidity and mortality weekly report (2018). PMID: 29494566 ↗
L5OTHERCited in: Supportive Care and Complication Management - [208]
Tarantola A, Crabol Y, Mahendra BJ et al.. “Caring for patients with rabies in developing countries - the neglected importance of palliative care.” Tropical medicine & international health : TM & IH (2016). PMID: 26806229 ↗
L5OTHERCited in: Supportive Care and Complication Management - [209]
Alavi SM, Alavi L. “Epidemiology of animal bites and stings in Khuzestan, Iran, 1997-2006.” Journal of infection and public health (2008). PMID: 20701846 ↗
L5OTHERCited in: Supportive Care and Complication Management - [210]
Al-Quliti K, Qureshi A, Quadri M et al.. “Acute Demyelinating Encephalomyelitis Post-COVID-19 Vaccination: A Case Report and Literature Review.” Diseases (Basel, Switzerland) (2022). PMID: 35225865 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [211]
Flack T, Howington GT. “Selected infectious disease topics in the ED: Optimizing logistics to optimize care.” American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2025). PMID: 40459367 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [212]
Singh M, Mishra N, Baig SA et al.. “Bear Mauling Injuries in Maxillofacial Region: A Review of 30 victims from Eastern India.” Journal of maxillofacial and oral surgery (2025). PMID: 40453607 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [213]
Erickson BP, Feng PW, Liao SD et al.. “Dog bite injuries of the eye and ocular adnexa.” Orbit (Amsterdam, Netherlands) (2019). PMID: 29874471 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [214]
Müller T, Denzin N, Vos A et al.. “Incubation periods and mortality outcomes following rabies virus infection in mesocarnivorous reservoir hosts: implications for experimental design and veterinary policy - a review and meta-analysis.” Virology journal (2025). PMID: 41239379 ↗
L2aSR_OBSCited in: Prognosis and Long-term Outcomes - [215]
Phadke VK, Gromer DJ, Rebolledo PA et al.. “Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults.” Vaccine (2024). PMID: 39418686 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [216]
Candia-Puma MA, Pola-Romero L, Barazorda-Ccahuana HL et al.. “Evaluating Rabies Test Accuracy: A Systematic Review and Meta-Analysis of Human and Canine Diagnostic Methods.” Diagnostics (Basel, Switzerland) (2025). PMID: 40002563 ↗
L2aSR_OBSCited in: Prognosis and Long-term Outcomes - [217]
Mohanty P, Boro PK, Heydtmann S et al.. “Rabies in rural northeast India: A case report emphasising the urgency of the One Health approach.” One health (Amsterdam, Netherlands) (2024). PMID: 39802066 ↗
L4CASE_REPORTCited in: Prognosis and Long-term Outcomes - [218]
Pardeshi G, Sharma P, Ittiel A. “Rabies post-exposure prophylaxis in India: a SWOT analysis.” Therapeutic advances in vaccines and immunotherapy (2026). PMID: 41487407 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Long-term Outcomes, Prevention and Screening - [219]
Sargeant JM, Caughey A, Joy W et al.. “Animal-Related Research in the Arctic With a Focus on Animal Health and Zoonotic Disease: A Scoping Review.” Zoonoses and public health (2026). PMID: 41254454 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Long-term Outcomes - [220]
Mutsaka-Makuvaza MJ, Binuyo MO, Cyuzuzo C et al.. “The Burden of Neglected Tropical Diseases in Rwanda: A Scoping Review.” Health science reports (2025). PMID: 40831688 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Long-term Outcomes - [221]
Chen SJ, Rai CI, Wang SC et al.. “Infection and Prevention of Rabies Viruses.” Microorganisms (2025). PMID: 40005749 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Long-term Outcomes - [222]
Ávila-Vargas L, Soler-Tovar D, Dong Q et al.. “Anticoagulants for the Control of the Common Vampire Bat (Desmodus rotundus).” Zoonoses and public health (2025). PMID: 39710827 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Long-term Outcomes - [223]
Zhao D, Chen G, Wang S et al.. “A single ultra-low dose self-amplifying RNA rabies vaccine confers rapid and complete protection in mice.” Vaccine (2026). PMID: 41455183 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [224]
Zhang Z, Zhang J, Mu C et al.. “A Rabies Virus Nucleocapsid-like Nanostructure Vaccine Based on Dual-Cationic Lipid Nanoparticles.” Vaccines (2025). PMID: 41441663 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes, Prevention and Screening - [225]
Li H, Wei J, Zhou S et al.. “Metagenomic Next-Generation Sequencing Unmasks Atypical Rabies - Guangxi Zhuang Autonomous Region, China, 2024.” China CDC weekly (2025). PMID: 41098344 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [226]
Xu P, Fang J, Qin F et al.. “Brain-targeted extracellular vesicles for anti-cuproptosis therapy in subarachnoid haemorrhage.” Stroke and vascular neurology (2025). PMID: 40953925 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [227]
Cunningham A, Camilon T, Chao S. “Surgical Management of Pediatric Dog Bites: A Systematic Review and Treatment Guideline.” Journal of pediatric surgery (2025). PMID: 39462695 ↗
L2aSR_OBSCited in: Special Populations - [228]
Chokephaibulkit K, Huoi C, Tantawichien T et al.. “Noninferiority Study of Purified Vero Rabies Vaccine-Serum Free in 3-dose and 2-dose Preexposure Prophylaxis Regimens in Comparison With Licensed Rabies Vaccines.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39587931 ↗
L1bRCTCited in: Special Populations - [229]
Jin F, Zhu L, Wang Y et al.. “Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic.” Vaccine (2024). PMID: 38937182 ↗
L1bRCTCited in: Special Populations - [230]
Quiambao BP, Payumo RA, Roa C et al.. “A phase 2b, Randomized, double blinded comparison of the safety and efficacy of the monoclonal antibody mixture SYN023 and human rabies immune globulin in patients exposed to rabies.” Vaccine (2024). PMID: 38834432 ↗
L1bRCTCited in: Special Populations - [231]
Hou Q, Liu S, Liu C et al.. “Immunogenicity of 4-dose Essen intramuscular regimen for rabies post-exposure prophylaxis: A multi-center cross-sectional study in China.” Travel medicine and infectious disease (2024). PMID: 38992484 ↗
L2bTRIAL_NONRANDOMCited in: Special Populations, Guidelines and Resources - [232]
Surendran J, Hs R, Kumari N et al.. “A prospective study on health seeking behaviour and post exposure prophylaxis received by animal bite victims at the anti-rabies clinic in a tertiary care centre of urban Bangalore.” F1000Research (2024). PMID: 39015143 ↗
L2bCOHORTCited in: Special Populations - [233]
Júnior DST, Marques MSV, de Oliveira RC. “Adapted Milwaukee protocol for rabies treatment in a Brazilian indigenous child: case report.” Virology journal (2024). PMID: 39456043 ↗
L4CASE_REPORTCited in: Special Populations - [234]
Agarwal A, Rana S, Mathur SB et al.. “Immunogenicity of Three-session Intradermal Rabies Post-exposure Prophylaxis in Indian Children and Adolescents.” The Pediatric infectious disease journal (2026). PMID: 40966763 ↗
L5OTHERCited in: Special Populations, Guidelines and Resources - [235]
Baron JN, Peng YS, Martínez-López B et al.. “Analysis of predictors of rabies-positive biting animals in Cambodia using spatio-temporal Bayesian regression modelling.” PLoS neglected tropical diseases (2025). PMID: 40911623 ↗
L5OTHERCited in: Special Populations - [236]
Schnyder JL, van Sinderen K, Schipper-Boer N et al.. “Long-term immunogenicity and boostability of rabies pre-exposure prophylaxis (PrEP) in immunocompromised adults who received PrEP prior to the start of immunosuppressive therapy: an exploratory study.” Journal of travel medicine (2025). PMID: 40874561 ↗
L5OTHERCited in: Special Populations - [237]
Agarwal A, Singh C, Mathur SB et al.. “Immunogenicity and safety of the accelerated 2-dose intradermal rabies pre exposure prophylaxis regimen in immunocompetent and immunocompromised pediatric populations: a comparative study.” Infection (2025). PMID: 40779007 ↗
L5OTHERCited in: Special Populations, Guidelines and Resources - [238]
Chiu CY, Henao-Martínez AF, Agudelo Higuita NI. “Association between tick-bite history and safety of gelatin-containing vaccines: Analysis of a large database of the United States.” Ticks and tick-borne diseases (2025). PMID: 40752174 ↗
L5OTHERCited in: Special Populations - [239]
Wang Y, Sun H, Wu Y. “Advances in Adjuvanted Rabies Vaccines.” Vaccines (2026). PMID: 41746055 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [240]
Sharma R, Prajapati S, Bakshi H et al.. “A Prospective Study of the Epidemiological Profile of Dog Bite Cases and Determinants of Anti-Rabies Vaccination Compliance at a Rural Health Training Center from a Medical College in Gujarat.” Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine (2025). PMID: 41561727 ↗
L2bCOHORTCited in: Prevention and Screening - [241]
Formstone A, Miranda MEG, Cruz VDD et al.. “Process mapping the One Health response to a rabies outbreak in the Philippines.” BMJ global health (2026). PMID: 41927312 ↗
L5OTHERCited in: Prevention and Screening - [242]
Correa-Valencia NM, Lecuona-Olivares LA. “Perceptions and Barriers Regarding Rabies in Cats in the Americas: An Approach From the One Health Perspective.” Tropical medicine & international health : TM & IH (2026). PMID: 41913454 ↗
L5OTHERCited in: Prevention and Screening - [243]
Fotedar N, Shankariah HR. “Compliance with anti-rabies post-exposure prophylaxis among animal bite victims attending anti-rabies clinic of a tertiary care centre in urban Bengaluru.” BMC infectious diseases (2026). PMID: 41749175 ↗
L5OTHERCited in: Prevention and Screening - [244]
Haruna EG, Madaki PD, Udechukwu CC et al.. “Spatio-temporal patterns and vaccination effectiveness in rabies risk using surveillance data from Kaduna State, Nigeria.” BMC public health (2026). PMID: 41703514 ↗
L5OTHERCited in: Prevention and Screening - [245]
Swedberg C, Siddiqi UR, Keshavamurthy R et al.. “Chasing rabies herd immunity: evaluating dog vaccination strategies and post-vaccination survey reliability in urban and peri-urban Bangladesh.” Frontiers in microbiology (2025). PMID: 41640414 ↗
L5OTHERCited in: Prevention and Screening - [246]
Wang L, Li H, Zhang L et al.. “Changed Trends in Utilization and Substitution Pattern of Non-National Immunization Program Vaccines in Central China, 2011-2024.” Vaccines (2025). PMID: 41600932 ↗
L5OTHERCited in: Prevention and Screening - [247]
Sahin A, Karadag-Oncel E. “Rabies post-exposure prophylaxis in children: adherence to national guidelines in a country at ongoing risk.” BMC public health (2026). PMID: 41530740 ↗
L5OTHERCited in: Prevention and Screening - [248]
Hussein HA, Ahad AA, Abdilahi MH. “Rabies outbreak in Lefeisa town, Somali region, Ethiopia: A report on epidemiological trends and one health implications.” One health (Amsterdam, Netherlands) (2025). PMID: 41492299 ↗
L5OTHERCited in: Prevention and Screening - [249]
Amro A, Amro AM, Assi AK et al.. “Public knowledge, awareness, and practices regarding rabies in Palestine: a cross-sectional survey, 2025.” Frontiers in public health (2025). PMID: 41487648 ↗
L5OTHERCited in: Prevention and Screening - [250]
Zhao D, Zhao J, Chen X et al.. “A randomized, non-inferiority phase III clinical trial of immunogenicity and safety of 5-dose and 4-dose schedules of a freeze-dried human rabies vaccine (MRC-5 cells) in participants aged 10-60.” BMC infectious diseases (2025). PMID: 41466188 ↗
L5OTHERCited in: Prevention and Screening - [251]
Kone M, Plieskatt J, Thienta M et al.. “Efficacy of ProC6C-AlOH/Matrix-M against Plasmodium falciparum infection and mosquito transmission: a phase 2, randomised, controlled human malaria infection study.” The Lancet. Infectious diseases (2025). PMID: 41418800 ↗
L5OTHERCited in: Prevention and Screening - [252]
Liu X, Li Y, Li J et al.. “Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2023). PMID: 37211270 ↗
L1bRCTCited in: Guidelines and Resources - [253]
Pichon S, Moureau A, Petit C et al.. “Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study.” Vaccine (2022). PMID: 35778281 ↗
L1bRCTCited in: Guidelines and Resources - [254]
Tariku MK, Belete AH, Worede DT et al.. “Incidence of suspected human rabies virus exposure and associated risk factors in Ethiopia: systematic review and meta-analysis.” BMC infectious diseases (2025). PMID: 39762751 ↗
L2aSR_OBSCited in: Guidelines and Resources - [255]
Jiang X, Li J, Pan J et al.. “The epidemiology and clinical features of post-exposure prophylaxis for rabies: A retrospective study of 9772 cases.” One health (Amsterdam, Netherlands) (2024). PMID: 38725962 ↗
L2bCOHORTCited in: Guidelines and Resources - [256]
Fang Z, Tao X, Liu S et al.. “Validation of the Rapid Fluorescent Focus Inhibition Test for Rabies Virus Neutralizing Antibodies - China, 2025.” China CDC weekly (2026). PMID: 41837257 ↗
L5OTHERCited in: Guidelines and Resources - [257]
Lamere L, Sohail H, Robinson S. “Leveraging Syndromic Surveillance for Rabies Postexposure Prophylaxis Surveillance in Maine, 2018-2022.” Public health reports (Washington, D.C. : 1974) (2026). PMID: 41635032 ↗
L5OTHERCited in: Guidelines and Resources - [258]
Nam LH, Nguyen-Tien T, Lindahl JF et al.. “A one health approach to prioritizing emerging zoonotic diseases (EZDs) in northern Vietnam.” One health (Amsterdam, Netherlands) (2025). PMID: 41492292 ↗
L5OTHERCited in: Guidelines and Resources - [259]
Chen Q, Yin W, Zhu Z et al.. “The Clinical Advantages of Anti-Rabies Monoclonal Antibodies in Post-Exposure Prophylaxis - Worldwide, 2016-2025.” China CDC weekly (2025). PMID: 41098348 ↗
L5OTHERCited in: Guidelines and Resources - [260]
Ludmer S, Crum D, Wallace R et al.. “Rabies Outbreak in an Urban, Unmanaged Cat Colony - Maryland, August 2024.” MMWR. Morbidity and mortality weekly report (2025). PMID: 40839527 ↗
L5OTHERCited in: Guidelines and Resources - [261]
Zhang N, Xu X, Zhang M et al.. “A Comprehensive Analysis and Forecast of Rabies Epidemic and Elimination Challenges - China, 2005-2023.” China CDC weekly (2025). PMID: 40832061 ↗
L5OTHERCited in: Guidelines and Resources - [262]
Chen Q, Cai L, Lv X et al.. “Circulating Antibody's Role During Post-Exposure Prophylaxis, and Beyond for Rabies: A Review.” Vaccines (2025). PMID: 40733752 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [263]
Tarango M, Kolby JE, Goodman OLB et al.. “Going batty: US bat imports raise concerns for species conservation and human health.” One health (Amsterdam, Netherlands) (2025). PMID: 40104217 ↗
L5OTHERCited in: Guidelines and Resources - [264]
Ploin D, Alexandre M, Ventelou B et al.. “Prioritisation of infectious diseases from a public health perspective: a multi-criteria decision analysis study, France, 2024.” Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (2024). PMID: 39668764 ↗
L5OTHERCited in: Guidelines and Resources - [265]
Stein SR, Beron AJ, Nelson KM et al.. “Notes from the Field: Enhanced Surveillance for Raccoon Rabies Virus Variant and Vaccination of Wildlife for Management - Omaha, Nebraska, October 2023-July 2024.” MMWR. Morbidity and mortality weekly report (2024). PMID: 39418219 ↗
L5OTHERCited in: Guidelines and Resources - [266]
Ouyang H, Zhao Z, Fall IS et al.. “Spatial-temporal distribution of neglected tropical diseases burdens in China from 2005 to 2020.” Infectious diseases of poverty (2024). PMID: 39232824 ↗
L5OTHERCited in: Guidelines and Resources - [267]
Ghosh S, Hasan MN, Nath ND et al.. “Rabies control in Bangladesh and prediction of human rabies cases by 2030: a One Health approach.” The Lancet regional health. Southeast Asia (2024). PMID: 39140082 ↗
L5OTHERCited in: Guidelines and Resources - [268]
Scher G, Yankowski C, Kurup D et al.. “Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease.” NPJ vaccines (2024). PMID: 39122759 ↗
L5OTHERCited in: Guidelines and Resources - [269]
Butala CB, Cave RNR, Fyfe J et al.. “Impact of COVID-19 on the neglected tropical diseases: a scoping review.” Infectious diseases of poverty (2024). PMID: 39075616 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [270]
Auerswald H, Guillebaud J, Durand B et al.. “Bayesian modeling of post-vaccination serological data suggests that yearly vaccination of dog aged <2 years old is efficient to stop rabies circulation in Cambodia.” PLoS neglected tropical diseases (2024). PMID: 38635851 ↗
L5OTHERCited in: Guidelines and Resources